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ABSTRACT
The paradigm shift in cancer treatments from traditional chemotherapeutics to
targeted therapies has rapidly improved prognoses for patients for whom cancer was
once a death sentence. This is especially true in the case of targeted immune therapies
which activate the body’s own natural defense system to fight cancer. Despite these
advances, however, cancer remains the second leading cause of death in the United
States. The promise of targeted therapeutics has faced significant hurdles in providing
effective cancer treatments, namely the limited percentage of susceptible cancers for
each treatment, high cost burden, high toxicities, and significant risk of treatment induced
resistance. As a result, targeted therapies are often combined into a cocktail of multiple
drugs, including other targeted therapeutics and chemotherapies. These hurdles have led
to a resurgence of interest in natural products to treat cancer. Natural products tend to
be cheap, safe to use, and capable of targeting multiple cellular pathways at once. Multitargeting natural products which simultaneously affect multiple cellular processes
including angiogenesis, metastasis, immune response, and apoptosis are uniquely
positioned to provide a robust treatment for cancer when used alone or in combination
with current targeted therapeutics.
This study investigates the anticancer properties of two natural products,
clusianone and deacetylnemorone. The compounds were screened against 60 cancer cell
lines to determine the growth inhibitory properties of the compounds. Both compounds
v

were found to inhibit cancer cell growth across all nine of the tissue types screened at
doses of 10 µM or less. Clusianone subsequently induced cell death in 25 of the cell lines
screened at 100 µM concentrations, while deacetylnemorone only induced cell death in
one melanoma cell line SK-MEL-5 at 10 µM. Clusianone was further shown to target
tubulin polymerization and induce dose dependent apoptosis in non-small cell lung
cancer. The compounds were additionally assayed in vitro to determine their effects on
angiogenesis, macrophage polarization, and cancer cell invasion. Both compounds were
shown to reduce tube formation between endothelial cells, a crucial step in angiogenesis,
and inhibit cancer cell invasion into cell free gaps. Finally, clusianone was shown to
increase the expression of TNF-𝛼 and IL-6 in THP-1 derived macrophages, suggesting
polarization to an M1, anticancer state. The multi-targeting nature described may allow
these compounds to simultaneously induce cell death directly in tumor cells, starve
tumors by reducing their blood supply, limit the invasion of cancers into healthy tissue,
and stimulate the immune system to attack cancer cells. This multipronged attack would
provide treatments which are less susceptible to resistance when used alone in addition
to enhancing the effects of targeted therapies when used in combination. Clusianone and
deacetylnemorone are therefore promising drug leads for anticancer therapy.

vi

TABLE OF CONTENTS
Dedication ........................................................................................................................... iii
Acknowledgements............................................................................................................. iv
Abstract ................................................................................................................................ v
List of Tables ..................................................................................................................... viii
List of Figures ...................................................................................................................... ix
List of Abbreviations ........................................................................................................... xi
Chapter 1: Introduction ...................................................................................................... 1
Chapter 2: The use of natural products to target cancer stem cells .................................. 4
Chapter 3: A multi-targeting abietane diterpenoid with growth inhibitory and antiangiogenic properties re-sensitizes chemotherapy resistant cancer ............................... 38
Chapter 4: A multi-targeting natural product with chemotherapeutic, immunemodulating, and anti-angiogenic properties .................................................................... 65
Chapter 5: Summary ....................................................................................................... 105
References ...................................................................................................................... 109
Appendix A: Supplementary tables and figures ............................................................. 120
Appendix B: Permission to reprint .................................................................................. 134

vii

LIST OF TABLES
Table A.1: Primers used for quantitative real-time polymerase chain reaction ............ 120
Table A.2: Percent growth of the 60 cell lines examined in the NCI-60 five dose screening
method. The cancer cell lines are organized by tissue type ........................................... 121

viii

LIST OF FIGURES
Figure 2.1: Illustration of the Cancer Stem Cell Model’s explanation for tumor formation,
metastasis, and recurrence and the potential of natural products in their treatment ... 36
Figure 3.1: The structure of the abietane diterpenoid, deacetylnemorone. ................... 58
Figure 3.2: Waterfall plot of the growth percent of 59 cell lines in response to 10 µM of
deacetylnemorone, determined by the NCI-60 one dose screening test. ....................... 59
Figure 3.3: Percent viability of MG-63, SK-OV-3, MDA-MB-231, HCT 116, HCT 116/200,
and A2780ADR cells in response to various concentrations of deacetylnemorone ........ 60
Figure 3.4: The percent viability and cell number of the HCT 116/200 cell line in response
to a 48 hour exposure of various concentrations of deacetylnemorone, alone or in
combination with the chemotherapy agent FdUrd .......................................................... 61
Figure 3.5: Histogram of propidium iodide expression as measured by flow cytometry for
SK-MEL-5 cells treated with either a vehicle control or 15 µM of deacetylnemorone .... 62
Figure 3.6: Invasion of SK-MEL-5 melanoma cells into a cell-free gap created using a 2well cell culture insert when incubated with different concentrations of
deacetylnemorone for 24 hours ....................................................................................... 63
Figure 3.7: The average number of junctions, or tubes, formed between HUVEC
endothelial cells after 8 hours .......................................................................................... 64
Figure 4.1: The structure of the polyprenylated acylphloroglucinol natural product,
clusianone ......................................................................................................................... 92
Figure 4.2: Waterfall plot of the GI50, TGI, and LC50 of clusianone for 60 cell lines as
determined by the NCI-60 five dose screening assay....................................................... 93
Figure 4.3: Percent growth of NCIH460 non-small cell lung cancer cells after 48 hours of
treatment with clusianone in the NCI-60 panel ............................................................... 96

ix

Figure 4.4: Cell cycle flow cytometry experiment showing the histogram of propidium
iodide expression of NCIH460 cells after four different time points of treatment with
either a vehicle control or clusianone .............................................................................. 97
Figure 4.5: Annexin V/propidium iodide expression of NCIH460 cells exposed to a vehicle
control, 7.6 µM clusianone, 15 µM clusianone, 35 µM clusianone, or 61 µM clusianone
for 48 hours ....................................................................................................................... 98
Figure 4.6: Expression of apoptosis-related proteins in NCIH460 cells after treatment
with clusianone as determined by electrophoresis followed by western blot analysis... 99
Figure 4.7: Invasion of NCIH460 cells into a cell free gap created using a 2 well cell
culture insert consisting of two wells that were separated by a wall ............................ 100
Figure 4.8: Tube formation between HUVEC endothelial cells after 8 hours of incubation
on growth factor reduced BD MatrigelTM with or without clusianone........................... 101
Figure 4.9: The extent of tubulin polymerization when exposed to clusianone as
determined by absorbance at 340 nm for 1 hour .......................................................... 102
Figure 4.10: Inhibition of 135 tyrosine kinases treated with 20 µM of clusianone
determine using the DiscoverX scanTK kinase panel ..................................................... 103
Figure 4.11. Gene and cytokine expression of macrophages treated with clusianone . 104
Figure A.1: The 1H-NMR, 13C-NMR, H-H COSY, HSQC, and HMBC spectra of the abietane
diterpenoid, deacetylnemorone ..................................................................................... 124
Figure A.2: The negative ion mode time of flight-mass spectrometry and negative mode
HR-MS spectra of deacetylnemorone used to determine molecular weight................. 127
Figure A.3: Viability of SK-MEL-5 cells after 6, 12, or 24 hours of incubation with
deacetylnemorone .......................................................................................................... 128
Figure A.4: The 1H-NMR spectrum, 13C-NMR spectrum, H-H COSY spectrum, HSQC
spectrum, and HMBC spectrum of clusianone in DMSO ................................................ 129
Figure A.5: Time of flight mass spectrum determination of molecular weight for
clusianone ....................................................................................................................... 132
Figure A.6: Cell viability and invasion of macrophages in response to incubation with
clusianone ....................................................................................................................... 133

x

LIST OF ABBREVIATIONS
ABC .......................................................................................................ATP-binding cassette
ABCB1 .............................................................................................. ATP binding cassette B1
ALDH............................................................................................. Aldehyde dehydrogenase
ALK (C1156Y) .............................................................. Anaplastic lymphoma kinase C1156Y
ATCC ................................................................................ American Type Culture Collection
ATRA .................................................................................................. All-Trans Retinoic Acid
BAA .....................................................................................................BODIPY-aminoacetate
BAAA ........................................................................................ BODIPY-aminoacetaldehyde
BCA ............................................................................................................Bicinchoninic acid
BCRP .................................................................................. Breast cancer resistance protein
BRAF ............................................................................ B-rapidly accelerated fibrosarcaoma
BSA .................................................................................................... Bovine serum albumin
CAR-T cell ...........................................................................Chimeric antigen receptor T-cell
CD133 ..................................................................................... Cluster of differentiation 133
CD24 .............................................................................................. Cluster of differentiation
CD243 ..................................................................................... Cluster of differentiation 243
CD44 ......................................................................................... Cluster of differentiation 44
cDNA ....................................................................... Complementary deoxyribonucleic acid
CNS .................................................................................................. Central nervous system
xi

COSY ....................................................................................... H-H correlation spectroscopy
CSCs ........................................................................................................... Cancer stem cells
CT ................................................................................................................. Cycle threshold
DAPI ........................................................... 4’,6-diamidino-2-phenylindole, dihydrochloride
DEAB.......................................................................................... Diethylaminobenzaldehyde
DHC ............................................................................................................ Dihydrocapsaicin
DMSO ...................................................................................................... Dimethyl sulfoxide
DOX ............................................................................................ Doxorubicin hydrochloride
EDTA .................................................................................. Ethylenediaminetetraacetic acid
EGM-2 ............................................................................ Endothelial cell growth medium-2
ELISA .......................................................................... Enzyme-linked immunosorbent assay
EMT ................................................................................ Epithelial-mesenchymal transition
epCAM.............................................................................. Epithelial cell adhesion molecule
ER ..................................................................................................... Endoplasmic reticulum
ESA ............................................................................................... Epithelial specific antigen
FACS .............................................................................. Fluorescence-activated cell sorting
FBE........................................................................................................ Fetal Bovine Essence
FDA ....................................................................................... Food and Drug Administration
FdUrd.............................................................................................. 5-fluoro-2’-deoxyuridine
GAPDH ........................................................... Glyceraldehyde 3-phosphate dehydrogenase
GI50 ............................................................................................... Growth inhibition of 50%
HA ........................................................................................................................Hyaluronan

xii

HAS ......................................................................................................... Heat stable antigen
HMBC ...................................................................Heteronuclear multiple bond correlation
HRP .................................................................................................. Horseradish peroxidase
HSQC .................................................................. Heteronuclear single quantum coherence
HTS ............................................................................................. High throughput screening
HUVEC ........................................................................................ Human umbilical vein cells
IL-6.....................................................................................................................Interleukin-6
JAK3 ................................................................................................................ Janus kinase 3
LC50 .......................................................................................... Lethal concentration of 50%
LC-MS .............................................................. Liquid chromatography-mass spectrometry
MDR ............................................................................................... Multiple drug resistance
MDR1 ................................................................................... Multidrug resistance protein 1
MEK ............... Mitogen-activated protein kinase/extracellular signaling regulated kinases
MEM ......................................................................................... Minimum essential medium
MET ................................................................................ Mesenchymal-epithelial transition
MS .......................................................................................................... Mass spectrometry
mTOR................................................................................. Mechanistic target of rapamycin
MTS ....... 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2Htetrazolium
NCI-60....................................................................................... National Cancer Institute-60
NIH ........................................................................................ National Institutes of Health’s
NMR ........................................................................................ Nuclear magnetic resonance
NPs ............................................................................................................. Natural products
xiii

Oct4 ............................................................................Octamer-binding transcription factor
PARP ...................................................................................... Poly (ADP-ribose) polymerase
PBS .............................................................................................. Phosphate buffered saline
PD-1 .................................................................................. Programmed cell death protein 1
P-gp ............................................................................................................. P-glycoprotein 1
PI ................................................................................................................Propidium iodide
PI3K ............................................................................................. Phosphoinositide 3-kinase
PMA ................................................................................................ 12-myristate 13-acetate
PMSF ..................................................................................... Phenylmethylsulfonyl fluoride
PTEN ................................................................................ Phosphatase and tensin homolog
RIPA ................................................................................. Radio-immunoprecipitation assay
RNA ............................................................................................................. Ribonucleic acid
RPMI ...................................................................................Roswell Park Memorial Institute
rT-PCR......................................................................... Real time-polymerase chain reaction
SDS ................................................................................................... Sodium dodecyl sulfate
SP.................................................................................................................. Side population
STAT3 ..................................................... Signal transducer and activator of transcription 3
TAMs .................................................................................. Tumor associated macrophages
TBS.......................................................................................................... Tris buffered saline
TBST..............................................................................................................TBS with Tween
TGF-ß ................................................................................ Transforming growth factor beta
TGI .................................................................................................... Total growth inhibition

xiv

TICs .......................................................................................................Tumor initiating cells
TMB .................................................................................................... Tetramethylbenzidine
TNFα ......................................................................................... Tumor necrosis factor alpha
TOF-MS............................................................................. Time of flight mass spectrometry
VEGF ........................................................................ Vascular endothelial cell growth factor

xv

CHAPTER 1
INTRODUCTION
The treatment of cancer has been revolutionized by the advent of targeted
therapies. These therapies take advantage of our ever-evolving understanding of cancer
biology and cellular pathways, by specifically interacting with key cancer associated
proteins. This represents a dramatic shift from traditional chemotherapeutics, which
were used to induce cell death in a wide range of cancer cell types through a variety of
mechanisms, from causing DNA damage to interfering with microtubule function.
Targeted therapies have expanded the universe of suitable cancer treatments from the
primarily cytotoxic molecules of traditional chemotherapies to a range of therapies which
may induce cell death, activate the immune system to attack cancer cells, or inhibit the
formation of new vasculature to the tumor environment. Due to the targeted nature of
these therapies, they can be tailored to very specific cancer morphologies, increasing
efficacy in applicable patients.
Despite these advances, however, cancer remains the second leading cause of
death in the United States1. The results gleaned from the clinical use of targeted therapies
have been disappointing due to the major setbacks associated with their use. One major
hurdle is the cost associated with the treatments. The low population of patients
treatable with each developed therapy in combination with the expense of drug
development can lead to prohibitive treatment cost to the patient. This is particularly
1

apparent in the case of the chimeric antigen receptor T-cell (CAR-T cell) therapy
tisagenlecleucel, which is made by isolating a patient’s T-cells and genetically engineering
them to target cancer cells when re-introduced into the body. This personalized
treatment, while effective, costs approximately $475,0002.
Another major setback for targeted cancer treatments is the limited number of
patients treatable with each developed therapy. As targeted therapeutics are engineered
to affect a specific molecule, tumors with little expression or limited reliance on the target
protein of a particular therapy cannot be effectively treated with that therapy. For
example, the anti-programmed cell death protein 1 (PD-1) therapy nivolumab, is a
targeted therapy which blockades the immune checkpoint process leading to cancer cell
evasion from the immune system. However, this therapy has been shown to be
ineffective at treating cancers with low mutational burden or low immunogenicity3.
Arguably one of the most problematic hurdles faced by targeted therapies is
acquired resistance to treatment. Many of these therapies are initially effective for
applicable patients but quickly lose efficacy as the patient is treated. This could be due to
increased expression of cancer stem cells, upregulation of unrelated cellular survival
pathways, or alterations in the structure or expression of the target protein in response
to the treatment. Targeted therapies from kinase inhibitors to angiogenesis inibitors, such
as sorafenib and bevacizumab, have been limited by the development of resistance4-6. As
a result of these challenges, targeted therapies are often combined with other unique
targeted therapies or traditional chemotherapeutics to increase their efficacy and limit
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the occurrence of treatment resistance. This thesis investigates the potential of natural
compounds to be used in these cancer treatment cocktails.
Natural products possess the unique ability to influence multiple cellular targets
simultaneously. As a result, these compounds are suggested for use in conjunction with
targeted therapy/chemotherapeutic mixtures synergizing with multiple components of
the cocktail, affecting unrelated cancer related pathways, and reducing the possibility for
developed resistance. In the following chapters, the potential of natural products for the
treatment of cancer is evaluated. In Chapter 2, a literature review is provided to give a
brief background on the use of natural products to treat cancer. Specifically this review
details the use of multi-targeting natural products to target cancer stem cells, inhibiting
the invasion, metastasis, and drug resistance of cancer. Following this literature review,
two specific compounds which were screened for anti-cancer properties from a library of
natural products are presented. Chapter 3 details the use of the abietane diterpenoid,
deacetylnemorone, to simultaneously inhibit cancer cell growth, inhibit cancer cell
invasion, inhibit angiogenesis, and re-sensitize treatment resistance cancers to
chemotherapy. Chapter 4 discusses the acylphloroglucinol, clusianone, a natural
compound capable of inducing apoptosis in non-small cell lung cancer, inhibiting
angiogenesis, and modulating the immune system. Potential mechanisms of action for
clusianone are also discussed in this chapter. Finally, the findings of this study are
summarized in Chapter 5.
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CHAPTER 2
THE USE OF NATURAL PRODUCTS TO TARGET CANCER STEM CELLS1
2.1 ABSTRACT
The cancer stem cell hypothesis has been used to explain many cancer
complications resulting in poor patient outcomes including induced drug resistance,
metastases to distant organs, and tumor recurrence. While the validity of the cancer stem
cell model continues to be the cause of much scientific debate, a number of putative
cancer stem cell markers have been identified making studies concerning the targeting of
cancer stem cells possible. In this review, a number of identifying properties of cancer
stem cells have been outlined including properties contributing to the drug resistance and
metastatic potential commonly observed in supposed cancer stem cells. Due to cancer
stem cells’ numerous survival mechanisms, the diversity of cancer stem cell markers
between cancer types and tissues, and the prevalence of cancer stem cell markers among
healthy stem and somatic cells, it is likely that currently utilized treatments will continue
to fail to eradicate cancer stem cells. The successful treatment of cancer stem cells will
rely upon the development of anti-neoplastic drugs capable of influencing many cellular
mechanisms simultaneously in order to prevent the survival of this evasive
subpopulation. Natural compounds represent a historically rich source of novel,

1

Taylor, W.F. and Jabbarzadeh, E. 2017. Am J Cancer Res. 7: 1588-1605.
Reprinted here with permission of publisher.
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biologically active compounds which are able to interact with a large number of cellular
targets while limiting the painful side-effects commonly associated with cancer
treatment. A brief review of select natural products that have been demonstrated to
diminish the clinically devastating properties of cancer stem cells or to induce cancer stem
cell death is also presented.
2.2 INTRODUCTION
Modern chemotherapy, radiotherapy, and other antineoplastic regimens have
made the treatment of many solid tumors possible and have given hope to those
diagnosed with cancer. However, the prognosis for many cancer patients remains bleak
due to the high rate of cancer recurrence and multiple drug resistance (MDR) seen after
initial chemotherapy treatments. Metastatic cancers affecting multiple organ systems are
particularly difficult to treat and oftentimes demand the partial or complete surgical
resection of multiple tissues. Cancer stem cells (CSCs) potentially explain many of the
shortcomings of established chemotherapy treatments.
CSCs are distinguished as a small population of tumor cells which are able to form
phenotypically diverse tumors, as wells as self-renew and differentiate. They are
described as belonging to a group of tumor initiating cells (TICs) which may or may not
possess stem-like characteristics, but debate remains as to how large a proportion of TICs
are indeed stem-like. Additionally, it is not clear whether or not the plasticity of tumor
cells allows any cell to become stem-like and gain the capability to recapitulate
heterogeneous tumors. The role of CSCs in tumor formation was first identified by Bonnet
and Dick in the late 90s 7. In this paper, the CD34+/CD38- subpopulation of cells from acute

5

myeloid leukemia were shown to form tumors in immunodeficient NOD/SCID mice with
higher efficiency than the CD34+/CD38+ subpopulation. The ability of CSCs to
asymmetrically divide, allowing the CSC to self-renew as well as differentiate to produce
a heterogeneous tumor containing multiple cell phenotypes, was also identified. Since
this discovery, the CSC hypothesis has been tested rigorously, and evidence that CSCs play
a crucial role in tumor development for many different cancers has been reported. These
include breast carcinoma8, 9, colorectal carcinoma

10

, head and neck squamous cell

carcinoma 11, hepatocellular carcinoma 12, 13, lung carcinoma 14, ovarian adenocarcinoma
15

, glioblastoma 16, and pancreatic carcinoma 17 among others.
According to the CSC model, cancer recurrence after treatment is due to the

superior resistance of CSCs to cellular toxins and insults. While current treatments are
capable of eradicating the bulk of the tumor mass, the lingering CSCs are able to form
new, fully developed tumors from a small number of cells or even a single cell. CSCs are
thought to resist treatment through several cellular mechanisms including the
overexpression of drug efflux pumps, quiescence, and detoxifying enzymes18. A high
population of CSCs within a tumor has subsequently been linked to MDR and a poorer
prognosis for cancer patients 19. Furthermore, the cellular machinery of CSCs has been
shown to allow for epithelial-mesenchymal transition (EMT), a process by which epithelial
cells lose their cell-to-cell and/or cell-to-matrix adhesion and can survive in a migratory
state 20. By undergoing EMT, migrating to other organs, and reattaching by mesenchymalepithelial transition (MET), CSCs are hypothesized to initiate the formation of metastatic
tumors.

6

Current methods for the treatment of cancer have been demonstrated to be
insufficient in eliminating CSC populations from a number of cancer types. CD133+ glioma
CSCs have been shown to resist radiation therapy to a higher degree than their CD133counterparts

21

. Breast CSCs exhibit a similar resistance to radiotherapy in addition to

common chemotherapy treatments

22, 23

. Furthermore, the CSC population in residual

breast cancer tumors has been shown to increase significantly following chemotherapy
treatments, nearly doubling the tumorigenic potential of the residual cancer cells in
immunodeficient SCID mice 23. Treatments targeting a specific molecule or surface marker
are likely to fail to eliminate CSCs due to the multiple survival pathways activated in CSCs
in addition to the ambiguity of CSC markers across different tissue types, the presence of
commonly used CSC markers in healthy tissues, and the often required combination of
markers used to denote CSC populations. Treatments capable of reducing CSC
populations will therefore require the development of novel, diverse, and multi-targeted
approaches for cancer treatment. Due to the numerous, still poorly understood
characteristics of CSCs, the discovery of CSC targeting therapies will likely be the result of
opportunistic screening of new or known compounds against CSC populations.
Natural products may be the key to discovering novel treatments demanded by
the difficulty of treating CSCs. Natural products (NPs) have been a historically rich source
of biologically active compounds for the pharmaceutical industry. The value of NPs in
medicine is a result of their ability to influence multiple signaling pathways
simultaneously while producing diminished, benign side effects. The success of these
compounds, especially as they relate to cancer treatment, has led researchers to
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investigate the effect of a number of NPs on CSCs. Figure 2.1 summarizes the role of CSCs
in cancer formation, metastasis, and relapse in addition to the potential role of natural
products in their treatment. In this review, properties distinguishing CSCs as well as
properties which give rise to the drug resistance associated with CSCs are identified. A
brief review of select NPs which have been shown to target CSCs is also provided.
2.3 IDENTIFYING CANCER STEM CELLS
One of the major challenges facing cancer stem cell research is accurately defining
which tumor cell subpopulations are stem like. The gold standard for identifying CSCs
remains the ability of a small number of cells to generate a fully developed tumor when
injected into immunocompromised mice, but the cost, time, and labor associated with
animal studies have led to the search for markers of stem like cancer cells. Many putative
CSC markers have been proposed and subsequently identified as targets for
chemotherapeutics. However, the expression of these markers has been shown to be
inconsistent across CSCs from different tissues and tumor phenotypes 24, 25. Additionally,
many of the reported CSC markers are possessed by healthy stem cells and even noncancerous, non-stem-like cells, posing a challenge to the development of targeted
therapies based upon these markers.
Oftentimes, a combination of supposed CSC markers is required to denote the CSC
population. For example, a common population of cells within breast cancer that has been
deemed breast cancer stem cells are CD44+/CD24-/ESA+ 8. The most notable among these
putative markers are the surface proteins CD44 and CD133 which have been used to
identify CSCs in a wide array of cancer types. In addition to these supposed markers,

8

certain properties of CSCs have also been use to distinguish them from the rest of the
tumor population. For example, cells known as the side population (SP) have been shown
to possess a high percentage of TICs 13, 15, 16. Tumors cells within the SP are distinguished
by their ability to exclude Hoechst 33342 fluorescent stain which is typically assessed via
flow cytometry.
Investigators have attempted to isolate populations of CSCs using these properties
combined with flow cytometric techniques or selective growth environments. Using these
purified populations of CSCs, their tumorigenic properties and specific responses to drug
candidates can be better investigated. Low purity of isolated populations, the ability of
CSCs to differentiate into phenotypically diverse populations, and disagreement over
which markers should be used to identify CSCs still pose major hurdles to many of these
techniques. A brief review of common CSC markers and characteristics used to identify or
isolate CSC populations is provided below.
2.3.1 CD44
Cluster of differentiation 44 (CD44) is a very commonly utilized marker for CSCs.
CD44 proteins are integral membrane glycoproteins which play a role in cell attachment
to the extracellular matrix by binding to hyaluronan (HA). CD44 is often used in
combination with other markers to denote CSCs; however, in cases such as head and neck
squamous cell carcinoma, CD44 has also been used alone to identify cancer cells capable
of self-renewal and differentiation 11. The expression of this marker has been used as a
putative marker for cancer stem cells in such tissues as breast 8, ovarian 26, pancreatic 27,
and bladder

28

along with many others. CD44 regulates the growth, migration, and
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invasion characteristic of CSCs in addition to modifying the extracellular matrix of tissues
to support new tumor formation 29, 30. Interestingly, cells expressing CD44 also produce
a higher amount of the cytokine transforming growth factor beta (TGF-ß) which has been
shown to aid EMT 31. Further, HA-CD44 binding activates protein kinase Ce, which in turn
phosphorylates the stem cell maintenance transcription factor, Nanog. Nanog then
begins a signaling cascade which results in the upregulation of ATP binding cassette B1
(ABCB1), a drug efflux pump, contributing to MDR 30. Reducing the population of CD44
expressing cells in tumor populations, therefore, has the potential to diminish the CSC
population and limit invasion, metastases, and drug resistance in a broad spectrum of
cancers.
2.3.2 CD133
Cluster of differentiation 133 (CD133) is a pentaspan surface membrane protein
that is also commonly used as an indicator of CSCs. Interest in this marker as an indicator
of CSC was generated by its original use as a hematopoietic stem cell marker 32. CD133
has been identified as a CSC marker in glioblastomas 31 as well as colorectal 10, ovarian 33,
34

, hepatocellular 12, lung 14, and pancreatic 35 cancers. CD133 is localized to membrane

protrusions and microvilli, but little is known about the function of this protein in cells or
CSCs in particular. It is apparent that while CD133 can be used to distinguish CSC
populations, it may not play a direct or critical role in cancer formation or CSC
maintenance. A study demonstrating this point showed that a CD133+ colon cancer
population was able to differentiate and self-renew even when CD133 expression had
been knocked down 36. What is clearer is that CD133 has been positively correlated with
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poor outcomes for cancer patients. A meta-analysis of 603 gastric cancer patients from 8
different studies revealed that CD133 overexpression was linked to lymph node
metastasis, distant metastasis, higher drug resistance, an increased relapse rate, and a
lower 5-year survival rate

37

. The widespread presence of CD133 in putative CSC

populations across numerous tissues, coupled with the poor prognosis of patients
overexpressing CD133, validates this marker as a dependable marker for CSCs as well as
a potential cancer drug target.
2.3.3 CD24
Cluster of differentiation (CD24) is yet another surface marker used to demarcate
CSC populations. CD24 is a notable CSC marker as both its presence

17

and absence 9, 38

has been used to denote CSC phenotypes depending upon the tissue. CD24 is a surface
expressing glycoprotein, also known as heat stable antigen (HSA), which was initially
identified as a marker for hematopoietic subpopulations, typically B-cells. Numerous
functions have been suggested for this protein, including signaling and cell attachment,
and its expression can be seen in various cell types, most commonly acting as a marker of
differentiation for hematopoietic and neuronal stem cells. CD24 is often seen in the
context of adaptive immune response in which its expression can be seen in pre or
immature-B cell populations or in activated T-cells 39. The function of CD24 in tumor cells
may be explained by the association of the marker with P-selectin, a molecule expressed
by platelets and vascular endothelium, which may play an important mechanistic role in
cancer cell adhesion and metastasis. In addition to acting as positive or negative marker
for CSCs, depending upon the tissue of origin, the expression of CD24 has also been
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associated with poor prognosis, larger tumors, and lymph node metastasis in a range of
cancers, demonstrating its influence on clinical outcomes 40-42.
2.3.4 ESA OR EPCAM
Epithelial specific antigen (ESA), also known as epithelial cell adhesion molecule
(epCAM) has been used to identify CSCs from breast 9, colorectal 43, and pancreatic
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cancer. As the name implies, ESA is a surface marker typically expressed on epithelial cells,
which regulates cell-to-cell adhesion. ESA is overexpressed in a majority of epithelial
cancers, such as colorectal cancer, and as a result it has been the subject of numerous
studies and targeted chemotherapy strategies. ESA has further been linked to the
migratory and invasive capabilities of breast cancer and is highly expressed in breast
cancer metastases 44. By disrupting the expression of ESA, the migration and invasion of
cancer cells in vivo can be diminished. The upregulation of this transmembrane
glycoprotein, as a result, may play a role in the metastatic potential of proposed CSCs.
2.3.5 ALDH ACTIVITY
Increased aldehyde dehydrogenase (ALDH) activity has been used to identify CSCs
with little technical difficulty. ALDH can refer to any number of enzymes classified as
aldehyde dehydrogenases which act to catalyze the oxidation of aldehydes entering or
produced within the body. By oxidizing aldehydes, these enzymes transform potentially
deleterious compounds into carboxylic acids, preparing them for cellular metabolism. In
this way they act to detoxify the cell. ALDH enzymes are highly expressed in liver cells, but
their expression has also been used to distinguish numerous progenitor cells including
hematopoietic stem cells

45

and neural stem cells
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among others. ALDH enzymes are

therefore theorized to contribute to stem cells’ robust ability to survive chemical stresses
throughout the body. The cytoprotective effect of ALDH enzymes utilized by these stem
cell populations, however, can also be used to protect CSCs from chemotherapy
treatments.
ALDH activity has been used to identify CSCs of various tissues including colon 47,
breast 48, head and neck squamous cell carcinoma 49, ovarian 50, and lung 51. ALDH1 is
commonly proposed to be the source of ALDH activity in CSCs, and its expression has been
widely used as a CSC marker. However, unspecific ALDH activity can also be utilized to
categorize cells as CSCs using the ALDEFLUOR assay. The ALDEFLUOR assay contains
BODIPY-aminoacetaldehyde (BAAA) which enters intact, viable cells and is oxidized by
ALDH enzymes producing fluorescent BODIPY-aminoacetate (BAA). This fluorescence can
be detected using fluorescent microscopy or flow cytometry. The non-cytotoxic nature of
ALDEFLUOR additionally enables sorting of live CSC populations via fluorescenceactivated cell sorting (FACS). Identification of CSCs using ALDH activity assays is a powerful
tool for cancer researchers due to this ability to separate viable subpopulations combined
with the association of ALDH activity with MDR.
2.3.6 HOECHST 33342 EXCLUSION
Hoechst 33342 is a stain capable of permeating intact cell membranes, which
produces blue fluorescence when bound to nuclear DNA. This property is used to visualize
nuclei, similar to 4’,6-diamidino-2-phenylindole, dihydrochloride (DAPI), while
maintaining cell viability. Stem cells and other cells overexpressing drug efflux pumps
possess the unique ability to exclude this stain, and as a result Hoechst 33342 exclusion
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has been used to label various progenitor cells such as hematopoietic stem cells 52. The
drug efflux pumps responsible for Hoechst 33342 dye exclusion may further contribute to
MDR in cancer cells. Hoechst 33342 excluding cells, also known as the side population
(SP), of tumors have therefore been investigated as a source of drug resistant CSCs. SP
cells have been shown to exhibit stem-like properties in hepatocellular 13, lung 53, ovarian
15

, breast

8

and other cancers as well as exhibiting enhanced drug resistance. Like the

ALDEFLUOR assay, segregation of hypothesized CSCs using Hoechst 33342 exclusion can
be combined with FACS techniques to isolate a viable CSC populations based upon a
characteristic associated with MDR.
2.3.7 EMT CAPABILITY
Epithelial-mesenchymal transition (EMT) is the process undergone by epithelial
cells in which the cells alter their morphology, lose their polarity, and break cell-cell or
cell-matrix adhesions. In this way, the cells gain mobility and invasive potential. EMT is an
essential process during development and wound healing, allowing epithelial cells to
produce a population of mobile cells able to migrate to target locations and reestablish
basal and apical polarity once there 20. CSCs are hypothesized to possess enhanced EMT
capability, enabling the cells to survive in the absence of cellular adhesion in addition to
enhancing their resistance to apoptosis. CSCs having undergone EMT are thought to then
reattach and produce metastatic tumors or circulate throughout the body in a dormant
state, only to become active years later and cause distant cancer relapse to occur. The
ability of CSCs to undergo EMT can be investigated by determining the expression of EMT
related proteins such as Twist, Snail, or N-cadherin 54.
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More commonly, however, EMT capability is assessed by removing any
opportunity for cellular attachment. This can be accomplished through the use of nonadherent well plates, stirred bioreactors, serum-free growth conditions, or encapsulation
in hydrogels. When in these conditions, cells without EMT capability will die leaving only
cells that have undergone the transition. The remaining cells often grow in what are
referred to as tumorspheres which have been shown to be enriched in CSCs in numerous
tissues

55-57

. A major drawback of using these selective growth environments is the

relatively low purity of CSCs in the resulting population. Further, CSCs within
tumorspheres of a large enough size are likely to differentiate into phenotypically diverse
cells. Still, drug discovery efforts directed at limiting the EMT capability of CSCs should be
encouraged as this ability lies at the heart of the spread and recurrence of cancer that
plagues many patients.
2.4 DRUG RESISTANCE IN CANCER STEM CELLS
While resistance to chemotherapy treatments is not necessary to define CSCs,
drug resistance is commonly associated with CSC populations. In fact, when resistance to
a drug is induced, an increase in the percentage of cells possessing CSC markers has been
observed 58. Resistance to specific chemotherapy agents in cancer cell lines is typically
promoted in vitro by exposing the cells to gradually increasing doses of the drug or by
exposing the cells to several cycles of clinically relevant chemotherapy doses followed by
drug free media to mimic the treatment patients actually receive. The enrichment of CSCs
following chemotherapy regimens observed both in vitro and in clinical studies

19

has

enormous implications on drug discovery efforts and future cancer treatment. Without
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the ability to target and kill CSCs, chemotherapy treatments will continue to leave
patients at risk for tumor recurrence and developed drug resistance. The following
proteins and properties of CSC are thought to contribute to drug resistance in CSCs and
therefore represent ideal targets for future chemotherapy or chemotherapy sensitizing
drug discovery efforts. It is important to note, however, that healthy stem cells share
many of the properties imparting drug resistance to CSCs, and as a result targeting these
properties may lead to unwanted side-effects on otherwise healthy tissues.
2.4.1 ABC TRANSPORTERS
ATP-binding cassette (ABC) transporters are transmembrane proteins that serve a
crucial cytoprotective role for healthy stem cells throughout the body. The function of
these proteins is to pump toxic compounds from the cell body before their deleterious
effects can occur. These pumps are able to act on a large variety of compounds including
many chemotherapeutic agents. The expression of ABC transporters has been used to
indicate CSC phenotypes in multiple tissues and also plays a role in developing the
multiple drug resistance (MDR) typical of CSCs 59. Members of the ABC transporter family
that appear to be highly expressed in CSCs include, but are not limited to, ABCB1, ABCG2,
and ABCB5 60. The expressions of these proteins have been suggested as markers for CSCs,
but the lack of appropriate antibodies makes their detection more difficult than
previously discussed markers. The ability of the SP to exclude Hoescht 33342 is a result of
ABC transporters, specifically ABCG2, making SP isolation an indirect method of CSC
isolation based upon ABC transporter expression 60.
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Many of the ABC transporter proteins have been “discovered” multiple times in
the context of chemotherapy resistance leading to confusion in their identification. For
example, ABCG2 is often referred to as breast cancer resistance protein (BCRP) alluding
to its ability to confer MDR to breast tumor cells. ABCG2 expression has been identified
in the drug resistant subpopulations of many cancer models including K562 chronic
myeloid leukemia cells

61

and MCF7 breast adenocarcinoma to name a few

62

. The cell

lines in these experiments were made resistant through selection with various
chemotherapies such as doxorubicin.
ABCB1 is another ABC transporter with multiple aliases. ABCB1 has been referred
to by the names multidrug resistance protein 1 (MDR1), cluster of differentiation 243
(CD243), and most commonly P-glycoprotein 1 (P-gp). ABCB1 contributes to the efflux of
many widely used chemotherapeutic agents including anthracyclines, vinca alkaloids, and
taxanes making it a highly clinically relevant MDR protein63. Reduction of the expression
of ABCB1 has been shown to lead to an increased chemotherapy sensitivity of colorectal
CSCs in addition to MDR cell lines of differing origin63. By targeting ABC transporters, the
unique resistance of CSCs can theoretically be reversed, sensitizing them to traditional
chemotherapy treatments.
2.4.2 ALDH ENZYMES
Another strategy CSCs employ in order to exhibit MDR is the rapid metabolization
of the chemotherapy agents they are subjected to. As mentioned previously, the presence
of ALDH enzymes and their activity is a commonly used marker to identify CSCs. ALDH
enzymes exert their effect by oxidizing aldehyde groups of drug molecules, preparing

17

them for future cell metabolism and thus detoxifying the cell. ALDH enzymes may also
play a role in the differentiation of healthy and malignant stem cells. Inhibition of ALDH
activity in ALDHhi/CD44+ putative breast CSCs convincingly resulted in a loss of MDR 64.
Interestingly, the inhibition of ALDH activity using diethylaminobenzaldehyde (DEAB)
further sensitized these CSCs to radiation therapy. By eliminating ALDH activity from
tumors, the breakdown of chemotherapeutic agents within the tumor will be slowed
resulting in a more effective treatment. Cytotoxic compounds which do not act as
substrates for ALDH enzymes or that reduce their activity may have a unique ability to
induce apoptosis in CSCs and act as more effective long-term treatments.
2.4.3 PRO-SURVIVAL SIGNALING AND STEM CELL MAINTENANCE
CSCs hijack many of the pro-survival signaling cascades and maintenance proteins
seen in healthy stem cells. In this way, CSCs have a tendency to survive cellular stresses
capable of eliminating differentiated cancer cells in a similar fashion to non-malignant
stem cells. For example, mechanistic target of rapamycin (mTOR) and signal transducer
and activator of transcription 3 (STAT3) play a role in the maintenance and proliferation
of healthy and cancer stem cells. The activation of phosphatase and tensin homolog
(PTEN) and subsequent inhibition of mTOR and STAT3 results in a significant decrease in
CSC viability and overall tumor drug resistance 65.
The stem cell maintenance proteins Wnt, Hedgehog, and Notch are also
upregulated in CSCs. These molecules play a major role in maintaining the stem-ness of
CSCs and activating the expression of stem cell related transcription factors such as
octamer-binding transcription factor (Oct4) and Nanog as well as influencing EMT 66. Stem
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cell maintenance proteins such as these ensure CSCs will continue to asymmetrically
divide, allowing the CSC phenotype to persist in a number of harsh conditions.
Dysregulation of these pathways is hypothesized to promote gradual CSC differentiation
leading to decreased tumor viability in response to chemotherapeutics, making them an
attractive target for the treatment of both bulk tumors and CSCs.
2.4.4 QUIESCENCE
Cellular quiescence is defined by a reduced occurrence of mitotic divisions within
a cell population. Quiescence is recognized as a trait of most somatic stem cells, allowing
them to survive in a state of relative dormancy and reduce the accumulation of DNA
mutations over time 67. While debate remains as to whether or not chemotherapy agents
have a diminished effect on quiescent cells, experiments on leukemia stem cells have
shown that forcing these cells out of their dormant state results in increased drug
sensitivity

68

. The hypothesis behind this pathway for MDR is that diminished cellular

metabolism, failure to proceed throughout the entirety of the cell cycle, and lack of DNA
multiplication allows CSCs to avoid activating the targets of many chemotherapeutic
toxins. Quiescence of CSCs not only potentially influences MDR, but also enables CSCs to
remain dormant at the site of the original lesion or migrate throughout the body for years
before attaching and initiating new tumors. Targeting the quiescence of CSCs has the
potential to increase the efficacy of current therapeutic methods against CSCs within the
original tumor as well as prevent CSCs from entering dormant states capable of initiating
new tumors in patients in remission.
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2.5 NATURAL PRODUCTS TARGETING CANCER STEM CELLS
Natural products (NPs) have played an important role in medicine for much of
recorded human history. The earliest recorded use of medicinal plants dates back
approximately 5000 years to a list of Sumerian drug recipes written on a clay tablet, but
there is evidence that Neanderthals may have used plants for medicinal purposes as far
back as 60,000 years ago

69, 70

. Even today many people in the world rely on medicinal

plants for their healthcare needs. It is estimated that 70-95% of people in most developing
countries use traditional medicine for their primary healthcare needs

71

. Traditional

Chinese and Ayurvedic medicine have historically served as primary healthcare for many
people in developing nations, and both systems have drawn the attention of
pharmocognosists from around the world.
Active compounds from various organisms have had great success as
pharmaceuticals. This is especially true in the case of cancer chemotherapeutics. Between
1981 and 2006, 63% of anticancer drugs being used came from NPs, were inspired by NPs,
or were synthesized from a natural pharmacophore 72. The most profitable chemotherapy
drug in history, taxol (or paclitaxel), is a natural product derived from the bark of the
Pacific Yew Tree 73. Taxol was discovered through a random screening of approximately
15,000 species of plants

49

, but targeted screening of known medicinal plants for

anticancer properties has also been historically successful. For example, the vinca
alkaloids vincristine and vinblastine have been used clinically in cancer therapies for over
50 years

74

. These compounds were isolated from the rosy periwinkle, Catharanthus

roseus, a plant used in both traditional Chinese medicine and Ayurvedic medicine.
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Bacteria have also been a source of successful anticancer agents. Anthracyclines, such as
doxorubicin, are isolated from certain Steptomyces bacteria and have been used to treat
breast cancer for decades 75.
With advances in technologies such as high throughput screening (HTS) and
combinatorial chemistry in the 90’s, the cancer related drug discovery efforts of many
pharmaceutical companies shifted to targeted therapies

76

. These targeted, receptor

specific therapies relied upon small synthetic molecules or antibodies that could act as
“magic bullets” to treat specific cancer cells. Combinatorial chemistry has allowed vast
libraries of new chemical entities to be generated synthetically which can be tested
against disease related targets. Thousands of compounds from combinatorial chemistry
libraries can be analyzed every day using HTS 77. In addition, advances in proteomics and
genomics have enabled researchers to attempt to model molecules that can interact with
specific biological targets. The initial success of these targeted therapies including Gleevec
and Herceptin led many to believe that traditional NP based drug discovery had become
obsolete 51.
However, the limited number of successful drug candidates from targeted
therapies, the relatively small number of cancers successfully treated with new therapies,
and the higher risk of cancer developing a resistance to treatment created a renewed
interest in natural product drug discovery in the late 2000’s

52

. The limited efficacy of

targeted therapies is of increased likelihood in CSCs, due to the lack of agreed upon
universal CSC markers and the many survival mechanisms which they employ. Numerous
NPs and their derivatives have shown early clinical success or have received FDA approval
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for the treatment of cancer since the recent renewal in their interest

52, 78

. Despite the

obstacles facing the screening of NPs using HTS, they have shown many advantages over
synthetic chemical entities. Natural products are thought to possess “privileged
structures” that are specialized to interact with biological targets allowing them to
influence multiple cellular pathways simultaneously. This ability is crucial in combatting
cancer and CSCs, as the robust survivability of cancer is often the result of many different
mechanisms. Additionally, the chemical character and diversity of NPs is more favorable
than that of synthetic molecules. When compared to synthetic libraries, NP libraries tend
to have more chiral centers, higher steric complexity, fewer heavy atoms, more solvated
hydrogen-bond donors and acceptors, and a larger variety of molecular properties

54

.

Furthermore, historic use of a medicinal plant from which a NP is isolated can speak to
the safety of compound for human consumption and the potential to limit side-effects.
The continued ability of natural compounds to compete with synthetic chemical
entities has shown that NP based drug discovery is still relevant and capable of advancing
the treatment of cancer. It is likely that the successful screening of NPs for cancer killing
potential can be successfully applied to screening for CSC targeting agents. A few
promising NPs have been utilized to target CSCs in vivo and in vitro. Figure 2.1 depicts the
role that such NPs may play in preventing cancer metastasis and recurrence. These
compounds may have the potential to sensitize CSCs to conventional treatments, directly
induce cell death in CSCs, force CSCs to differentiate, or prevent CSCs from entering a
dormant and more resistant state. A brief review of these compounds can be found
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below. The reader of this review is directed to other reviews for a more comprehensive
list of NPs capable of targeting CSCs 18, 79, 80.
2.5.1 POLYPHENOLS
Many natural products used as pharmaceuticals can be classified as polyphenols.
Polyphenols are structurally defined by the presence of aromatic benzene rings bonded
to hydroxyl groups, but they encompass a number of structurally diverse compounds.
These subgroups include flavonoids, stilbenes, tannins, lignans, and phenolic acids among
others. Polyphenols of various groups have been demonstrated to regulate inflammation,
angiogenesis, cell growth, invasiveness, and apoptosis in vitro 81. As a result, they have
been studied extensively in the context of cancer prevention and metastasis. Recently,
these investigations have been extended to determine the effect of polyphenols on CSCs.
The polyphenols resveratrol and curcumin are notable examples of NPs that have been
shown to exhibit cytotoxic effects on CSCs.
2.5.1.1 RESVERATROL
Resveratrol is a polyphenolic stilbene derivative most commonly found in the skin
of grapes and berries. It has undergone extensive examination for its anti-inflammatory
and antioxidant properties in addition to many other useful biological properties. These
attributes give resveratrol the attractive potential to act as a cancer chemopreventative.
Resveratrol has been shown to induce apoptosis and promote S-phase arrest of select
cancer cells. This potential was demonstrated in Hep G2 hepatocyte carcinoma cells in
vivo at concentrations ranging from 10 to 50 µM 82. At concentrations higher than 50µM,
however, resveratrol induced G1/G0 arrest which was confirmed in a separate study using

23

a number of ovarian cancer cell lines 82, 83. Resveratrol has further been shown to induce
cell death through a non-apoptotic mechanism at concentrations between 50 and 100
µM in a ovarian cancer cell lines 83. This variety of mechanisms demonstrates the ability
of resveratrol, like other NPs, to influence numerous biological mechanisms
simultaneously making it an attractive anticancer agent.
Resveratrol may also be able to eliminate CSC populations from tumors. The
compound has been shown in a study by Shankar et al to induce caspase-3/7 activated
apoptosis in CD44+/CD24+/ESA+ pancreatic CSCs at 10 to 30 µM concentrations. The study
also found that 10 to 20 µM resveratrol was able to inhibit both stem cell maintaining
factors, such as Nanog and Oct-4, as well as anti-apoptosis proteins of the Bcl-2 family in
the pancreatic CSCs. Additionally, EMT proteins, such as Snail and Slug, as well as the EMT
capability of the pancreatic CSCs in non-adherent conditions was inhibited in response to
10 to 20 µM of resveratrol. Further, the expression of the drug efflux pump ABCG2 was
inhibited after administration of 10 to 30 µM of resveratrol, potentially sensitizing the
cells to conventional chemotherapy treatments. The apparent ability of resveratrol to
target CSCs and act as a chemopreventative and anti-inflammatory drug was further
demonstrated using a mouse tumor model. The frequency of tumor formation in KrasG12D
mice, spontaneous pancreatic tumor forming mutants, was significantly diminished when
treated with resveratrol for 10 months 84. The ability of resveratrol to induce apoptosis in
CSCs as well as reduce their tumorigenic potential in vivo was additionally supported in a
CD24-/CD44+/ESA+ model of breast cancer stem cells. In this study, apoptosis was induced
in the breast CSCs through a FAS mediated pathway after incubation with 50 or 100 µM
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resveratrol. The tumorigenic potential of the cancer stem cells was significantly
diminished in female nude mice through the administration of either an oral gavage or
intraperitoneal injection of 22.4 kg/body weight of resveratrol, giving significant evidence
that resveratrol is able to disrupt tumor formation by targeting CSCs 85.
While resveratrol exhibits extremely promising anticancer effects in preclinical
studies in vivo and in vitro, resveratrol has failed to translate this success to clinical trials.
This is due, in large part, to extremely low bioavailability, high effective dosages, and the
rapid metabolism of resveratrol to glucuronide, sulfate, and hydroxylate conjugates 86, 87.
These conjugates, once absorbed into the bloodstream fail to provide the same health
benefits as free resveratrol. As a result, there have been efforts to engineer resveratrol
formulations or drug delivery systems aimed at increasing the bioavailability of
resveratrol. These include formulations to stabilize resveratrol in the body, formulations
to increase the aqueous solubility of resveratrol, and encapsulation of resveratrol in
various lipids, micelles, or polymer structures with the aim of sustained, concentrated,
and/or targeted release 86, 87.
2.5.1.2 CURCUMIN
Curcumin is another polyphenol which has been thoroughly investigated for its
anticancer properties. This compound is a major component of turmeric, a spice widely
used in Indian and many Middle-Eastern cuisines. Curcumin has been shown to exhibit
an anti-inflammatory effect and promote apoptosis in cancer cells 88. It has been used in
clinical trials demonstrating its safety at high doses and activity against pancreatic
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neoplasms in human patients despite its low bioavailability 89. The antitumor properties
demonstrated by curcumin have led to investigations of its potential to target CSCs.
Curcumin has been used to inhibit the formation of breast cancer mammospheres
in vitro by 50% and 100% using 5µM and 10µM concentrations, respectively,
demonstrating the ability of curcumin to inhibit CSC’s ability to undergo EMT

90

. An

analogue of curcumin, GO-Y030, was demonstrated to induce apoptosis, diminish
tumorsphere formation, and inhibit STAT3 phosphorylation in ALDH+/CD133+ colon CSCs
when used at 2 to 5µM concentrations. The ability of this analogue to target tumor
initiating cells was further demonstrated using a NOD/SCID mouse model. When given a
50 mg/kg intraperitoneal injection of GO-Y030, the average tumor weight resulting from
a xenograft implantation of 1 x 105 CSCs was diminished by 58.10%

91

. Curcumin has also

been suggested as a supplement to current chemotherapy treatments. Curcumin in
combination with FOLFOX, a commonly prescribed combination of leucovorin calcium,
fluorouracil, and oxaliplatin, was able to decrease the viability and diminish EMT of colon
CSCs to a higher extent than FOLFOX alone 92.
While curcumin shows great potential as an anticancer agent and has been used
in a number of clinical trials against cancer, it suffers similar shortcoming to resveratrol.
Namely, the rapid metabolism and excretion of curcumin, along with its hydrophobicity,
results in low bioavailability which has been demonstrated using mouse models

93, 94

.

Numerous drug delivery studies have been conducted to increase the bioavailability of
curcumin including the use of adjuvants to interfere with metabolism, encapsulation in
liposomes and nanoparticles, and the use of more stable structural analogues 95.
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2.5.2 FLAVONOIDS
Flavonoids are a major class of polyphenolic secondary metabolites found in
numerous medicinal plants. They are derived from flavone which contains two phenyl
rings and one heterocyclic ring. Flavonoids are commonly found compounds throughout
the plant kingdom, and as a result, they are widespread throughout the human diet. Due
to their abundance in fruits, vegetables, nuts, spices, and herbs, a flavonoid rich diet has
been suggested as a feasible means of cancer chemoprevention

96

. Certain flavonoids

including, quercetin and kaempferol, have been implicated as apoptosis inducers,
antioxidants, inflammation regulators, and angiogenesis inhibitors. Further, certain
flavonoids have been shown to have an effect on heat shock proteins, multiple drug
resistance, adhesion, metastasis, and angiogenesis

97

. The high number of CSC related

properties which seem to be affected by flavonoids have led to their investigation as CSC
targeting agents. A review of one such flavonoid, quercetin, is presented below.
2.5.2.1 QUERCETIN
Quercetin is a flavonol secondary metabolite found throughout many species of
plants. Quercetin is a known anti-inflammatory agent and anti-oxidant which has been
demonstrated to induce programmed cell death in many malignant cancer cell lines.
Quercetin has been shown to interfere with a number of cellular pathways associated
with the formation and maintenance of human cancers including down regulating P53,
inhibiting tyrosine kinase, inhibiting heat shock proteins, and inducing type II estrogen
receptor expression 98. Quercetin has further drawn attention as a potential CSC targeting
therapeutic.
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Not only has quercetin been shown to inhibit the proliferation of CD133+ colon
CSCs at a concentration of 75µM, but it also increases the sensitivity of these cells to
doxorubicin (Adriamycin). In fact, when combined with 50 µM quercetin, doxorubicin
doses were more effective at inhibiting CSC proliferation in vitro than doxorubicin doses
three times more concentrated but lacking quercetin 99. This finding demonstrates the
potential of quercetin and other natural products to enhance the use of other
chemotherapeutics to eliminate CSC populations. The use of lower doses of
chemotherapeutic agents in combination with natural products such as quercetin may
result in diminished off target toxicity while also inducing apoptosis in CSCs, improving
patient outcomes, lowering the risk of cancer recurrence, and preventing metastasis
formation.
Other CSC models have been targeted using quercetin including CD44+/CD133+
prostate CSCs. At a concentration of 20 µM, quercetin lowers the viability of prostate
tumor spheroids grown in non-adherent flasks as well as diminish the migratory, invasive,
and colony forming potential of CD44+/CD133+ prostate CSCs 100. In this same publication,
quercetin was shown to synergize with epigallocatechin gallate, a catechin found in tea,
synergistically amplifying the above effects on these prostate CSCs. As is the case with
many other NP’s, however, quercetin’s poor solubility, poor permeability, and instability
result in diminished bioavailability 101. The relatively high dose of quercetin required to
elicit a biological response in combination with these issues warrant further drug delivery
efforts to increase the lifetime and concentration of the compound at the site of the
neoplasm.
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2.5.3 ALKALOIDS
Alkaloids are a class of pharmacologically active organic compounds distinguished
by the presence of nitrogen and aromatic rings in the chemical structure. Alkaloids are
produced throughout the plant kingdom, but are usually found in higher plants 102. Many
alkaloids have been used throughout history in the medical field from quinine for the
treatment of malaria to vinblastine for the treatment of multiple carcinomas. Several
alkaloids have been used clinically in the treatment of cancer with great success,
demonstrating their importance in the field. A small group of alkaloid compounds have
even been shown to differentiate between healthy and cancerous DNA, inhibiting in vitro
cancer DNA synthesis while leaving healthy DNA unaffected and resulting in a potential
cancer treatment with diminished side-effects 103. New investigations on alkaloids are still
being conducted showing further antineoplastic, anti-metastatic, and MDR inhibiting
potential 82. These results suggest a potential for alkaloids to eliminate CSCs, and indeed,
a number of compounds belonging to the alkaloid family have been shown to target CSCs
in vitro and in vivo. Three promising anti-CSC alkaloids, dihydrocapsaicin, piperine, and
berberine, are presented in the following sections.
2.5.3.1 DIHYDROCAPSAICIN
Capsaicin is the secondary metabolite and alkaloid responsible for the hotness of
many species of pepper. Dihydrocapsaicin (DHC), a saturated derivative of this
compound, has exhibited numerous anti-neoplastic properties. DHC has been shown to
induce dose-dependent and catalase regulated autophagic cell death in colon and breast
cancer cells when used at concentrations between 50 and 400 µM
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104

. However, when

autophagic cell death was inhibited through treatment with the inhibitor 3methyladenine, DHC instead induced caspase-3 activated apoptosis in these cell lines.
Further, when apoptosis was inhibited by the addition of peptide zVAD, autophagic cell
death was enhanced. This ability to promote separate modes of cell death is a useful tool
in targeting CSCs due to the many cell death evading pathways active in CSCs. This ability
further highlights the potential of NPs to influence multiple cellular mechanisms and
produce a robust cytotoxic effect on cancer cells.
A review of CSC related patents revealed that DHC is further hypothesized to
exhibit a cytotoxic effect on neural CSCs 79. In one of the patents collected in the review,
US20090076019A1, a neurosphere assay was invented to screen potential drugs for
activity against neural stem cells. As the percentage of putative CSCs are increased in
cancer neurospheres, compounds capable of inducing cell death in these spheres can be
thought of as agents targeting neural CSCs. DHC was identified in this patent as one of
several lead compounds which showed an ability to target CD133+ neural CSCs. The high
IC50 values of DHC, however, limit its use as an effective chemotherapeutic agent,
especially when one considers the low bioavailability common for many NPs. Further
research is warranted to determine if DHC or an analogue can target any phenotype of
CSCs with higher efficacy than what has been shown.
2.5.3.2 PIPERINE
Piperine is a promising antineoplastic alkaloid found in black and long pepper. The
use of piperine has previously been suggested as a cancer chemopreventative, but it has
also demonstrated the ability to induce cell cycle arrest, endoplasmic reticulum stress,
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and apoptosis when exposed to colon cancer in vivo at concentrations between 75 and
150 µM 105. The treatment of colon cancer cells with piperine has been shown to reduce
the ability of the cells to form non-adherent spheres and colonies, suggesting the
inhibiting effect of piperine on CSCs. The apoptotic effect of piperine has additionally
been confirmed using prostate cancer cells 106.
The ability of piperine to target stem cells specifically has been investigated in a
breast tissue model. After pre-treatment with 5 to 10 µM piperine, the mammosphere
formation potential, ALDH expression, and Wnt signaling of unsorted breast tissue was
significantly diminished 90. Interestingly, the differentiated population of these cells was
seemingly unaffected by the piperine treatment. The potential of piperine to target CSCs
without affecting other cells is a fantastic example of the robust ability of NPs to influence
molecular pathways while imparting only benign side effects. Piperine has additionally
been suggested for use in combination therapies with compounds, such as resveratrol or
curcumin, due to its ability to inhibit metabolic pathways. By slowing the glucuronidation
of these compounds, piperine inhibits the metabolism and clearing of NPs and increases
their bioavailability 107. By inducing a cytotoxic effect on CSCs and increasing the efficacy
of other compounds, piperine acts as an ideal complementary medication to other NP
chemotherapies.
2.5.3.3 BERBERINE
Berberine is a tetracyclic, isoquinoline alkaloid found in the roots and stems of
numerous plants. Berberine producing medicinal plants have been used as antiinflammatories in Ayurvedic medicine for years, and the compound has been shown to

31

induce dose-dependent apoptosis, initiated by reactive oxygen species generation, in a
broad spectrum of cancers 108, 109. The apoptosis induced by berberine goes through an
internal caspase-9 dependent pathway which results in a loss of mitochondrial membrane
integrity. Like many natural products, the bioavailability of berberine is low in the body,
limiting the potential of berberine as a drug. This obstacle is being overcome through the
use of targeting liposomes as a drug delivery system

110

. This delivery system

encapsulated berberine into liposomes which were engineered to deliver the compound
directly to the mitochondria of CD44+/CD24− breast cancer stem cells. Using this system,
1-50 µM of berberine was able to produce dose-dependent apoptosis in breast CSCs. The
drug was further able to induce the expression of the pro-apoptotic protein Bax and
activate caspase-9 and caspase-3 leading to apoptosis in CSCs isolated from MCF-7
mammospheres.
Additionally, berberine has been used to inhibit the expression of ABC
transporters responsible for MDR in CSCs

84

. Diminishing MDR, especially in CSC

populations, makes berberine an attractive complementary medicine when currently
accepted cytotoxic agents are unable to kill cancerous cells. An in vivo mouse model in
which MCF-7 breast CSCs were injected into female nude mice followed by an array of
berberine treatments and formulations demonstrated this synergistic capability. A
mixture of 10 mg/kg of berberine liposomes and 10 mg/kg of paclitaxel liposomes was
able to reduce the average tumor size in these mice by 85.5% compared to the control
after just 21 days 110. In this way, berberine could be used to either target CSCs alone or
in combination with traditional chemotherapy agents.
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2.5.4 OTHER
Many other natural compounds which do not fit into the classifications of
polyphenols, flavanoids, or alkaloids have shown promise in targeting CSCs. Retinoids are
an example of these compounds. Vitamin A, also known as retinol, generates a number
of biologically active retinoids, including All-Trans Retinoic Acid (ATRA). ATRA has found
clinical success in the treatment of acute promyelocytic leukemia under the trade name
Tretinoin. The drug is marked by its successful induction of remission coupled with
relatively mild side effects

111

. The mechanism of action utilized by ATRA is through

induction of cellular differentiation of leukemic and hematopoietic cells, and this
differentiation induction has further been observed in other types of stem cells 112. The
differentiation potential of retinoids presents a unique potential for cancer treatment,
namely differentiating CSCs into a cell population more sensitive to classic
chemotherapeutic regimens. Additionally, ATRA acts as an inhibitor of ALDH activity,
potentially reversing a cause of MDR in CSCs
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. ATRA has thus been used to limit the

tumorsphere formation ability and CSC percentage of breast cancer cells in vivo 113.
The lactone antibiotic brefeldin A is another NP that cannot be classified as a
polyphenol, flavonoid, or alkaloid. It has shown anticancer potential in a number of cancer
types including leukemia, colon, and prostate through p53 independent mechanisms 114,
115

. Brefeldin A is produced by certain fungal organisms and acts as a protein transport

inhibitor, preventing proteins from traveling from the endoplasmic reticulum (ER) to the
Golgi apparatus. Subsequently, brefeldin A initiates ER stress, potentially leading to its
apoptotic effects. Recently, brefeldin A has been shown to preferentially induce cell death
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in suspension cultures over adherent cultures of the human breast adenocarcinoma line
MDA-MB-231. In the same publication, brefeldin A also down-regulated the expression
of CD44, reduced the ability of the cells to form colonies in soft agarose, and reversed the
EMT

116

. Preferential killing of putative CSCs and inhibition of colony forming potential

was similarly reported in the human colorectal cancer line Colo 205 117. This preferential
killing has the potential to diminish CSC populations while limiting the side effects
typically associated with chemotherapy.
2.6 CONCLUSION
The cancer stem cell hypothesis, while still being investigated, presents
explanations to many of the issues facing cancer treatment today. The CSC hypothesis
explains the mechanisms underlying cancer recurrence, metastasis, and, to a degree,
multiple drug resistance. Cancer treatments directed toward the eradication of CSCs
could lead to higher survival rates and brighter prognoses for patients who fear cancer
regression could occur at any time. Current cancer treatments are insufficient in regard
to the eradication of CSC populations, likely due to the multitude of survival mechanisms
utilized by CSCs and the lack of definitive, universal, single molecule targets that separate
CSCs from healthy stem or somatic cells. Natural products have historically been an
excellent source of bioactive compounds capable of targeting multiple pathways, and
current investigations are underway to screen NPs for their effect on the CSC population
of numerous cancer types. Many different NPs have exhibited a range of CSC inhibitory
properties, and it is likely that more have yet to be discovered. As a result, NPs should
continue to be screened as potential chemotherapy agents, complimentary treatments
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for compounds already in clinical use, and cancer prevention molecules with special
attention focused on their ability to target CSCs. Further, due to the limited bioavailability
and rapid metabolism of many NPs, these drug discovery efforts must be coupled with
continued efforts to engineer robust drug formulations and delivery systems.
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2.8 FIGURES

Figure 2.1: Illustration of the Cancer Stem Cell Model’s explanation for tumor formation,
metastasis, and recurrence and the potential of natural products in their treatment.
Cancer Stem Cells (CSCs) are either formed upon carcinogenesis of somatic cells or stem
cells, or they are activated after a period of dormancy (1). These CSCs then asymmetrically
divide resulting in a phenotypically diverse tumor consisting of both CSCs and non-stemlike cells (2). Left untreated, the tumor will continue to grow and invade the surrounding
tissue, and CSCs undergoing EMT may break off from the original tumor and travel to
distant organs (3). The CSCs which reattach throughout the body can then initiate a new
tumor, resulting in metastases (4). Using current treatment methods capable of inducing
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cell death in the bulk of tumor cells, the CSCs are not destroyed due to their enhanced
survival traits, such as quiescence and the expression of ALDH enzymes and ABC
transporters (5). The remaining CSCs may then go on to recreate the original tumor,
sometimes increasing the percentage of CSCs within the tumor and forming multiple drug
resistant tumors (6). In other cases, the remaining CSCs will enter a state of dormancy
within the body and remain undetected for long periods of time before reactivating and
initiating the formation of a new tumor, thus resulting in cancer relapse in patients
thought to be cancer free (7). As a result of these issues, new treatments are being
investigated which can target CSCs. Natural products have shown the potential to induce
cell death in CSCs, cause CSCs to differentiate, or sensitize CSCs to conventional
chemotherapy treatments (8). Once the CSCs have been eliminated, the remaining tumor
may diminish in size and can be subsequently eradicated through the use of conventional
antineoplastic therapies (9).
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CHAPTER 3
A MULTI-TARGETING ABIETANE DITERPENOID WITH GROWTH INHIBITORY
AND ANTI-ANGIOGENIC PROPERTIES RE-SENSITIZES CHEMOTHERAPY
RESISTANT CANCER2
3.1 ABSTRACT
Targeted therapies have become the focus of much of the cancer therapy research
conducted in the United States. While these therapies have made vast improvements in
the treatment of cancer, their results have been somewhat disappointing due to acquired
resistances, high cost, and limited populations of susceptible patients. These hurdles
often necessitate combining targeted therapies together, or using them in conjunction
with chemotherapy in order to achieve an effective treatment. Using currently available
treatments, an estimated 609,640 cancer related deaths will occur in the United States
by the end of 20181. Compounds which target more than one cancer related pathway are
rare, but have the potential to synergize with multiple components of these cancer
treatment cocktails, increasing the cocktail’s efficacy and limiting resistance. Natural
products, as opposed to targeted therapies, typically interact with multiple cellular
targets simultaneously, making them a potential source of synergistic cancer treatments.
One such natural product, deacetylnemorone, has been previously shown to inhibit

2

Taylor, W.F., Moghadam, S.E., and Jabbarzadeh, E. 2019. To be submitted to Scientific
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cancer cell growth, but little is known about its ability to target other cancer related
pathways. In this study, deacetylnemorone was screened for its ability to inhibit cancer
cell growth, synergize with existing chemotherapy, inhibit cancer cell invasion, and inhibit
angiogenesis. The compound was found to inhibit cell growth in a broad spectrum of
cancer cell lines and selectively induce cell death in SK-MEL-5 melanoma cells.
Interestingly, the growth inhibitory properties of deacetylnemorone was stronger in
FdUrd resistant HCT 116/200 colorectal cancer cells when compared to the parent cell
line. The compound also enhanced the effect of FdUrd in HCT 116/200 cells when used at
concentrations as low as 0.3 µM, suggesting the compound could be used to reverse
acquired chemotherapeutic resistance. Furthermore, deacetylnemorone was able to
inhibit the formation of vascular tubes between endothelial cells, a crucial step in
angiogenesis, in addition to inhibiting the invasion of SK-MEL-5 melanoma cells, indicating
the compound could inhibit the processes required for cancer metastasis. Combined,
these results demonstrate that deacetylnemorone affects multiple cancer-related targets
related to tumor growth, drug resistance, and metastasis. Thus, the multi-targeting
natural product, deacetylnemorone, has the potential to enhance the efficacy of current
cancer treatments as well as reduce commonly acquired treatment resistance.
3.2 INTRODUCTION
Despite continuing advances in the treatment of cancer, it remains the second
leading cause of death in the United States according to the Centers for Disease Control
and Prevention1. In recent years, there has been a shift in research efforts focusing on
cancer drug discovery from cytotoxic chemotherapy agents, which induce cell death in
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rapidly dividing cells relatively indiscriminately, to targeted therapeutics, which influence
specific cancer-related pathways. Targeted therapies including immune modulating
therapies, such as monoclonal antibodies118, cytokines119, dendritic cell therapies120,
chimeric antigen receptor T cells (CAR-T cells)121, and immune checkpoint blockade
therapies122, as well as kinase inhibitors, such as cyclin dependent kinase inhibitors4,
tyrosine kinase inhibitors5, and phosphoinositide 3-kinase (PI3K) inhibitors123 have
changed the landscape of cancer treatment. Targeted therapies such as bevacizumab,
sorafenib, ziv-aflibercept, and vandetanib have also emerged to inhibit angiogenesis, a
process of new blood vessel formation essential to wound healing, that is sometimes
hijacked by cancer to feed growing and newly formed tumors6, 124.
While these targeted therapies have led to a surge of improved prognoses, they
have also come with drawbacks limiting their success in treating patients. For example,
immune modulating targeted therapies, including sipuleucel-T and tisagenlecleucel,
activate the immune system against cancer by isolating immune cells from the patient’s
body, altering their activity, and re-introducing the cells back into the patient2, 125. While
these methods provide effective and innovative treatment, they can cost hundreds of
thousands of dollars per injection2. Furthermore, this large price tag also comes with
strong side effects, including neurotoxicity, high fever, and respiratory distress126. Other
targeted therapies, such as the anti-programmed cell death protein 1 (PD-1) drug
nivolumab are less patient-tailored but suffer from a high risk of developed resistance
and a low population of susceptible patients127. Similarly, therapies targeting cancer cell
growth, such as tyrosine kinase inhibitors, often suffer from acquired resistance following
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the first few rounds of treatment. Angiogenesis targeting therapies come with their own
set of complications as well. Like other targeted therapies, angiogenesis targeting
therapies trigger treatment resistance, in part due to the plasticity of the tumor
microenvironment manipulated by the tumor cells themselves6. Upregulation of proangiogenic factors128, recruitment of pro-angiogenic cells129, and increased pericyte
coverage130 has been observed in response to anti-angiogenesis treatments and may be
responsible for anti-angiogenesis resistance. Additionally, angiogenesis-targeting
therapies lead to increased hypoxia in the tumor microenvironment, resulting in
increased tumor aggression and resistance to radiotherapy and chemotherapy131, 132.
As a result of these challenges, targeted therapies are often administered in
combination or in conjunction with chemotherapies in order to limit resistance and
increase efficacy. Of course, angiogenesis-targeting therapies can also act against this
combinatorial approach by limiting the drug delivery of other anti-cancer agents to the
tumor6. The shortcomings of targeted therapies have led to a renewed interest in natural
products for cancer treatment76. Compounds like natural products which are capable of
targeting multiple cancer associated pathways may provide a more robust cancer
treatment by limiting treatment acquired resistance, increasing the efficacy of multiple
components of cancer therapy cocktails, and reducing the amount of drugs that are
necessary to administer in order to achieve a positive treatment response.
In addition to influencing multiple biological targets, natural products are typically
low cost and are associated with limited side effects. They have played an historically
important role in cancer treatment, making up or inspiring approximately 60% of cancer
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treatments between 1981 and 200672. Before the advent of targeted therapies,
cytotoxicity was the primary screening endpoint used to determine a natural product’s
potential as a chemotherapy agent. Now, however, natural products are investigated for
numerous anti-cancer properties, such as their potential to induce cancer cell death,
inhibit cancer cell growth and invasion, modulate the immune system, and inhibit
angiogenesis to name a few. A select set of natural products have been identified that
affect multiple cancer-related pathways simultaneously. For example, curcumin133,
emodin134, 135, and astragaloside IV136, 137, are thought to be capable of inducing apoptosis
in cancer cells in addition to modulating the immune response to tumor formation.
Curcumin138 has also been suggested, along with resveratrol139 and green tea catechins140,
as compounds that combine anti-proliferative and anti-angiogenic effects141. The widely
used natural product derived chemotherapeutic, taxol, which imparts its cytotoxic effect
by disrupting the microtubule cytoskeleton of cancer cells, may owe some of its success
as an anticancer agent to an ability to inhibit angiogenesis through vascular endothelial
cell growth factor (VEGF) suppression at low concentrations142. By affecting multiple
cancer related pathways simultaneously, natural products may be able to synergize with
multiple components of commonly used mixtures of targeted therapies and
chemotherapeutics, enhancing their efficacy and limiting resistance. However, of the
natural products that exhibit multi-targeted effects against cancer, many suffer from low
bioavailability and low efficacy at low concentrations, necessitating the continued search
for lead compounds.
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Deacetylnemorone is a natural product of the abietane diterpenoid family that
has been isolated from plants belonging to the genus Salvia. Like others from this class of
natural compounds, deacetylnemorone has been shown to exhibit growth inhibitory
properties in cancer cells, namely cervical and prostate cancer143. However, the antiproliferative effect of this compound has not been widely established, nor has any
mechanism of action been suggested. Furthermore, the effect of deacetylnemorone on
other cancer related pathways has not been fully explored. Herein, the anti-proliferative
effect of deacetylnemorone on multiple cancer tissue types, in addition to the effect of
deacetylnemorone on angiogenesis and cancer cell invasion is studied. Cell cycle analysis
was performed to gain insight into the compound’s mechanism of action. Finally, the
ability of deacetylnemorone to enhance the cytotoxic effect of chemotherapy in
treatment-resistant cancer cells was determined.
3.3 MATERIALS AND METHODS
3.3.1 DEACETYLNEMORONE SOURCE AND IDENTIFICATION
The

abietane

diterpenoid,

deacetylnemorone,

was

obtained

through

collaboration with the University of Basel. The structure of the compound, shown in
Figure 3.1, was determined by 1D and 2D nuclear magnetic resonance (NMR) in addition
to time of flight mass spectrometry (TOF-MS). NMR analysis of deacetylnemorone was
conducted using dimethyl sulfoxide (DMSO) as the solvent and a Bruker Avance III-HD 400
MHz. 1H-NMR,

13

C-NMR, H-H correlation spectroscopy (COSY), heteronuclear single

quantum coherence (HSQC), and heteronuclear multiple bond correlation (HMBC) were
performed for structural determinations. For mass spectrophotometry analysis,
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deacetylnemorone was dissolved in methanol and analyzed using liquid chromatographymass spectrometry on a Thermo Orbitrap Velos Pro. The generated spectra can be seen
in Figures A.1 and A.2. A stock solution of deacetylnemorone in DMSO at a concentration
of 20mM was used for all cell culture experiments.
3.3.2 NCI-60 SCREENING
Primary cytotoxicity screening of deacetylnemorone against 59 cancer cell lines
was performed using the National Institutes of Health’s (NIH) National Cancer Institute60 (NCI-60) screening program144. This assay utilizes a Sulforhodamine B viability assay
described by Shoemaker145 to assess the growth percent of 60 immortalized cancer cell
lines across 9 tissue types. One dose, 10 µM, of deacetylnemorone was tested. Only data
generated from 59 cell lines was reported, as the HOP-92 non-small cell lung cancer cell
line was excluded from the one dose screen. Growth percent between 0% and 100% in
response to a compound can be interpreted as growth inhibition, and a negative percent
growth is interpreted as cell death.
3.3.3 CELL CULTURE
MG-63 (osteosarcoma), SK-OV-3 (ovarian adenocarcinoma), MDA-MB-231 (breast
cancer), HCT 116 (colorectal carcinoma), HCT 116/200 (FdUrd resistant subclone of HCT
116 cells), A2780ADR (doxorubicin resistant subclone of the ovarian carcinoma A2780),
and HUVEC (normal human umbilical vein endothelial cells) were obtained and stored in
liquid nitrogen until use. MG-63, SK-OV-3, MDA-MB-231, and HCT 116 cell lines were
purchased from ATCC. A2780ADR cells were purchased from Sigma-Aldrich. HCT 116/200
cells were generously provided by Dr. Franklin G. Berger from the Center for Colon Cancer
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Research, where they were originally cultured146. Human umbilical vein cells (HUVEC)
were purchased from Lonza. The culture media used for MG-63 was minimum essential
medium (MEM;Corning) supplemented with 10% Fetal Bovine Essence (FBE;VWR) and 1%
penicillin/streptomycin solution (Corning). The culture media for SK-OV-3 cells was
McCoy’s

5A

Medium

(Sigma)

supplemented

with

10%

FBE

and

1%

penicillin/streptomycin. The growth media for A2780ADR cells was Roswell Park
Memorial Institute (RPMI) 1640 medium (Corning) supplemented with 10% FBE and 2mM
L-glutamine (ThermoFisher). The growth media used for MDA-MB-231, HCT 116, and HCT
116/200 cells was RPMI 1640 medium supplemented with 10% FBE and 1%
penicillin/streptomycin. The growth media for HUVEC cells was endothelial cell growth
medium-2 (EGM-2; Lonza BulletKit). All cells were maintained at 37 °C and 5% CO2.
3.3.4 MTS ASSAY
Cells were grown to approximately 80% confluency before being washed with
phosphate buffered saline (PBS; Corning) and typsinized using a 0.25% trypsin, 2.21 mM
Ethylenediaminetetraacetic acid (EDTA), and sodium bicarbonate solution (Corning).
Trypsinized cells were suspended in culture media and centrifuged at 2500 rpm for 5
minutes. Cell viability was confirmed using trypan blue (Gibco). Cells were then seeded
into 96 well plates (VWR). MG-63, SK-OV-3, and A2780ADR cells were seeded at a density
of 2,000 cells/well. MDA-MB-231 cells were seeded at a density of 5,000 cells/well. HCT
116 and HCT 116/200 cells were seeded at a density of 4,000 cells/well. HUVEC cells were
seeded at a density of 3,000 cells/well. For all cell types, 100 µL of cell culture media was
used. The cells were then incubated for 24 hours at 37 °C and 5% CO2 to allow for cell
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attachment. After cell attachment, the culture media was aspirated and replaced with
media containing deacetylnemorone. The vehicle control was 0.5% DMSO (Macron Fine
Chemicals) in culture media. Doxorubicin hydrochloride (DOX;Sigma), and 5-fluoro-2’deoxyuridine (FdUrd; Sigma), were used as positive controls. In combination studies,
deacetylnemorone and FdUrd were added to the same culture media then added to the
cells. At 48 and 72 hours, the cells were washed with PBS and culture media
supplemented with 20% 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4sulfophenyl)-2H-tetrazolium (MTS) solution (Promega) was added to the cells. The cells
were incubated for 2 hours, and the absorbance of each well at 490 nm was measured
using a Spectramax 190 microplate reader.
3.3.5 CELL CYCLE ANALYSIS
The effect of deacetylnemorone on the cell cycle of SK-MEL-5 melanoma cells was
determined using flow cytometry. First, cells were seeded into 6 well plates at a density
of 250,000 cells per well suspended in 2 mL of media. The cells were allowed to attach
overnight, then the media was replaced with media containing deacetylnemorone. The
cells were trypsinized with 0.25% trypsin and collected along with the drugged media at
6, 12, 24, 48, and 72 hours of treatment with deacetylnemorone. The detached cells were
centrifuged at 2500 rpm for 5 minutes and washed with ice cold PBS twice. After
centrifuging and discarding the supernatant, the pellet was suspended in 1 mL of ice-cold
PBS, which was then added dropwise to 3 mL of ice-cold 70% ethanol in deionized water.
The cells were fixed in this condition at 4° for at least 24 hours. After fixation, the cells
were centrifuged, the supernatant was discarded, and the pellet was suspended in
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FxCycle PI/RNase Staining Solution (Invitrogen) for 15 minutes. The final cell suspension
was analyzed using a BD LSR II flow cytometer. The percentage of cells in the sub-G1,
G0/G1, S, and G2/M phases of the cell cycle were determined using the resulting
histograms.
3.3.6 IN VITRO INVASION ASSAY
Cell migration of SK-MEL-5 melanoma cells was investigated by making a cell-free
gap with a 2 well culture- insert for 24 well plates (IbiTreat, Martinsried, Germany). The
insert was made up of two wells that were separated by a thin wall. In each of the two
wells of the insert, 70 µl of cell suspension containing 6×104 cells was added. Cells were
allowed to reach confluency for approximately 24 hours. The 2 well inserts were then
removed and any resulting cell debris was washed with PBS. Fresh culture media
containing either the vehicle control or deacetylnemorone was added to the cells, and
the plates were incubated at 37 °C and 5% CO2 for 24 hours. Images were taken at 6, 12,
and 24 hours after the addition of the treated media using a phase contrast Nikon Eclipse
Ti-E inverted microscope. Percent invasion was calculated by measuring the gap distance
at each time point and using the formula

invasion % =

(𝑊0 −𝑊𝑛 )
𝑊0

∗ 100% ,

in which Wn is the width of the gap at the desired time point, and W0 is the initial width
zero right after forming a cell-free gap. One representative well was stained and imaged
after the final time point. The media was first replaced with 400 µL of Cell Stain Solution
(Cell Biolabs, Inc) and the plates were incubated for 15 minutes at room temperature.
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Each well was washed with deionized water and allowed to air dry. Images were taken
using a phase contrast inverted microscope (Invitrogen EVOS FL Auto Cell Imaging).
3.3.7 TUBE FORMATION ASSAY
Growth factor reduced BD Matrigel (Corning) was stored at -20 °C. Before use, the
Matrigel was thawed on ice at 4 °C overnight. Next, 50 µL of Matrigel was added to each
well of an ice-cold 96-well plate and incubated at 37 °C and 5% CO2 for 30 minutes,
allowing a gel to form. A suspension of 20,000 HUVEC cells in 100 µL of cell culture media
treated with deacetylnemorone was added to each well. The vehicle control contained
only HUVEC cells suspended growth media. The junctions, or tubes, between the
endothelial cells were imaged using an Invitrogen EVOS FL Auto at 4x magnification and
manually counted.
3.4 RESULTS
3.4.1 DEACETYLNEMORONE INDUCES CONCENTRATION DEPENDENT CELL DEATH IN
IMMORTALIZED CANCER CELL LINES ALONE AND IN COMBINATION WITH FDURD
In order to determine the chemotherapeutic potential of deacetylnemorone, the
compound was screened against 59 cancer cell lines using the NCI-60 cancer panel. This
panel utilizes a sulforhodamine B cell viability assay to determine the percent growth of
cells treated with a compound of interest for 48 hours compared to cells treated with a
vehicle control. Only one concentration, 10 µM, of deacetylnemorone was screened
(Figure 3.2). This concentration inhibited the cell growth of 55 of the 59 cell lines tested,
including at least one cell line from each of the 9 tissue types investigated. Of the 55 cell
lines whose growth was inhibited by deacetylnemorone, one melanoma cell line, SK-MEL-
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5, exhibited cell death in response to 10 µM of the compound. The growth percent of SKMEL-5 was -23.8% after 48 hours of treatment. While deacetylnemorone was capable of
inhibiting the cell growth of each tissue type tested, it was particularly effective against
melanoma, inhibiting the cell growth of four melanoma cell lines by at least 80%. This
result suggested that the compound may be indicated for the treatment of melanoma.
To further assess the growth inhibition poperties of deacetylnemorone, a 3-dose
MTS assay screen of 6 immortalized cancer cell lines was performed (Figure 3.3). The six
cell lines examined were MG-63 (osteosarcoma), SK-OV-3 (ovarian cancer), MDA-MB-231
(breast cancer), HCT116 (colorectal carcinoma), HCT 116/200 (colorectal carcinoma), and
A2780ADR (ovarian cancer). In each cell line tested, dose-dependent cell growth
inhibition was observed. This inhibition was significant in each cell line at concentrations
less than or equal to 150 µM after 48 hours of treatment with deacetylnemorone.
Notably, the inhibitory effect of the compound was stronger in HCT 116/200 cells than it
was in HCT 116 cells. The HCT 116/200 cell line was derived from the HCT 116 cell line
through treatment with gradually increasing concentration of the chemotherapeutic
agent FdUrd146. This treatment induced resistance to FdUrd in the cell line compared to
HCT116 by selecting for a resistant variant of thymidylate synthase. By comparing the
doxorubicin control groups from Figures 3.3D and 3.3E, it was observed that the
HCT116/200 cell line had also developed a cross-resistance to doxorubicin. The high
sensitivity of the chemotherapy resistant HCT 116/200 cell line to deacetylnemorone
when compared to the parent cell line prompted an investigation of the combinatorial
effect of deacetylnemorone with FdUrd (Figure 3.4). Three concentrations of
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deacetylnemorone (3 µM, 30 µM, and 150 µM) were used to treat HCT 116/200 cells
either alone or in combination with FdUrd. Each of these concentrations of
deacetylnemorone significantly increased the growth inhibition of the 4µM FdUrd
treatment. Both the deacetylnemorone-alone treatment and the combination treatment
acted in a dose dependent manner.
3.4.2 DEACETYLNEMORONE DELAYS PROGRESSION OF THE CELL CYCLE THROUGH S AND
G2/M PHASES.
Due to the growth inhibitory properties of deacetylnemorone, cell cycle analysis
was performed on SKMEL5 melanoma cells exposed to the compound to gain insight into
the mechanism of action. SKMEL5 cells were treated with deacetylnemorone for 72
hours, analyzing the DNA content of the cells at 6, 12, 24, 48, and 72 hours by propidium
iodide (PI) staining followed by flow cytometry (Figure 3.5A). Using the generated
histograms, the percentage of cells in the sub-G1, G0/G1, S, and G2/M phases of the cell
cycle was determined (Figures 3.5B and 3.5C). Compared to the control, no increase in
sub-G1 cells through the 72 hour treatment was observed, suggesting no apoptotic cell
death was occurring. However, the treated group did exhibit a build-up of cells in the Sphase of the cell cycle through 24 hours of treatment, accompanied by a decrease in
G0/G1 cells. This was followed by gradual decrease in S-phase cells and a subsequent
increase in G2/M cells from 24 to 72 hours of treatment. These trends could be explained
by a slowing down of progress through the cell cycle for the first 24 hours of treatment,
followed by a gradual release of cells from the S-phase and G2-M phase between the 24
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and 72 hour period. It is possible that higher concentrations of the compound could
completely arrest progress through the cell cycle.
3.4.3 DEACETYLNEMORONE INHIBITS INVASION OF MELANOMA IN VITRO.
The effect of deacetylnemorone on melanoma cell invasion was also investigated.
A cell free gap was created between two regions of SK-MEL-5 melanoma cells using 2-well
cell culture inserts. When the culture inserts were removed, the cells were treated for 24
hours with 0.3 µM, 3 µM, and 30 µM of deacetylnemorone. At 6, 12, and 24 hours the
percent invasion into the cell free gap was measured (Figure 3.6). At each time point, the
percent invasion of melanoma cells decreased as the concentration of deacetylnemorone
increased. The inhibition of melanoma cell invasion was significantly lower (p < 0.05) than
the control when the cells were treated with 30 µM deacetylnemorone at each of the
tested time points (Figure 3.6B). Both the movement of the cell front and the migration
of single cells into the cell free gap was inhibited as the concentration of
deacetylnemorone was increased (Figure 3.6A). Trypan blue cytotoxicity assays were also
performed at each time point, revealing the inhibition of cancer cell invasion occurred at
lower concentrations of deacetylnemorone than was toxic to the cells (Figure A.3).
3.4.5 DEACETYLNEMORONE INHIBITS TUBE FORMATION OF ENDOTHELIAL CELLS, A
CRITICAL STEP OF ANGIOGENESIS.
The effect of deacetylnemorone on angiogenesis was investigated using a tube
formation assay (Figure 3.7). The assay consisted of HUVEC endothelial cells grown on a
Matrigel basement membrane in the presence of growth factors. Under these conditions,
cellular projections called “tubes” will begin to form between the cells (Figure 3.7B). In
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this study, tube formation was allowed to occur for 8 hours under control conditions or
with growth media treated with deacetylnemorone. The number of tubes or junctions per
field were manually counted in triplicate for the groups treated with the control (culture
media alone), 0.3 µM deacetylnemorone, and 3 µM deacetylnemorone, and a dosedependent decrease in tube formation between HUVEC endothelial cells was observed as
the concentration of deacetylnemorone was increased (Figure 3.7A). The decrease for
both the group treated with 0.3 µM deacetylnemorone and the group treated with 3 µM
deacetylnemorone was significant (p ≤ 0.05) when compared to the control treated
group. A representative image of the cells treated with 0.3 µM and 3 µM
deacetylnemorone can be seen in Figures 3.7C and 3.7D respectively. The toxicity of an 8
hour treatment of deacetylnemorone on HUVEC endothelial cells was also determined
using the MTS assay. No significant difference (p ≤ 0.05) in cell viability between HUVEC
cells treated with the vehicle control and the HUVEC cells treated with up to 30 µM
deacetylnemorone was observed (Figure 3.7E), indicating the compound was not
cytotoxic to HUVEC cells at the concentrations used to inhibit angiogenesis.
3.5 DISCUSSION
Multi-targeting natural products may create renewed vigor in the use of natural
compounds for the treatment of cancer. Targeted therapies hold great promise for the
future of cancer treatment but have been accompanied by numerous shortcomings,
including high rates of resistance, low rates of susceptible patients, and high cost. Natural
products that attack multiple cancer-related pathways may limit therapy-induced
resistance and provide robust treatment when in combination with currently available
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therapies. Deacetylnemorone was examined in this study to determine its ability to
interfere with multiple cancer-related pathways, including cancer cell growth and
proliferation, cancer cell invasion, and angiogenesis.
The growth inhibitory properties of deacetylnemorone were first examined by
submitting the compound to the NCI-60 one dose cytotoxicity screen. At 10 µM,
deacetylnemorone exhibited growth inhibitory properties across all nine of the tissue
types examined. Within each tissue type a range of activity was observed, from no growth
inhibition at all to inducing cell death in one melanoma cell line. These results suggest
that the growth inhibitory effects of deacetylnemorone are not tissue-type dependent.
However, the compound did appear to have a strong effect on multiple cell lines isolated
from melanoma. SK-MEL-5 is a melanoma cell line that exhibited a 23.8% reduction in cell
viability after 48 hours of treatment with deacetylnemorone. As a result, it appears that
at concentrations near 10 µM, deacetylnemorone is selective in inducing cell death. The
growth inhibition and cytotoxicity results across the 59 cell lines tested in the NCI-60
screen were less potent than other compounds that have undergone NCI-60 screening,
and thus further screening was not performed using the NCI-60 panel. However, dosedependent growth inhibition was demonstrated independently using an MTS viability
assay on MG-63, SK-OV-3, A2780ADR, MDA-MB-231, HCT 116, and HCT 116/200 cells.
Each of the six cell lines tested exhibited a dose-dependent response in cell viability to
deacetylnemorone. In each case, the viability of the cells treated with 150 µM of
deacetylnemorone was significantly less than the control (p ≤ 0.05). In the case of
colorectal carcinoma (HCT 116 and HCT 116/200) and breast cancer (MDA-MB-231), a
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significant decrease (p ≤ 0.05) compared to the control group at 30 µM of
deacetylnemorone was observed. This confirmed the selectivity noted in the NCI-60
screening.
Of particular interest was the seemingly greater sensitivity of the chemotherapy
resistant HCT116/200 cells to deacetylnemorone compared with the parent HCT 116 cell
line. Deacetylnemorone at 30 µM reduced the cell viability of HCT 116/200 after only 48
hours compared to the 72 hours needed for the parent cell line. The compound also
reduced the cell viability of the HCT 116/200 cell line to a greater extent than the parent
cell line at both the 30 and 150 µM concentrations. The compound may therefore be
targeting a cellular pathway that is responsible for the treatment-induced resistance of
HCT 116/200 cells or was co-selected with the cellular pathway responsible for the
treatment-induced resistance such as the percentage of cancer stem cells within the
population147. In order to further explore this interesting result, deacetylnemorone was
used in combination with the chemotherapy agent FdUrd to treat HCT 116/200 cells. The
cell viability of HCT 116/200 was significantly lower when deacetylnemorone was used in
combination with FdUrd than when FdUrd was used alone. This effect occurred at as little
as 3 µM deacetylnemorone, a concentration lower than the minimum required to reduce
cell viability when deacetylnemorone was used on this cell line alone. It is likely that a
synergistic rather than simply a combinatorial effect occurred when deacetylnemorone
was used alongside the chemotherapy.
Next, cell cycle analysis was performed to gain insight into the mechanism of
action for the cell growth inhibition of SK-MEL-5 melanoma cells. When compared to the
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control, deacetylnemorone at 15 µM did not increase the percentage of cells in the sub
G1 phase of the cell cycle, suggesting apoptotic cell death was likely not occurring. As a
result, another mechanism of cell death, such as necrosis or autophagy, is likely
responsible for any cell death observed at this dose148. Additionally, from 6 to 24 hours of
incubation with deacetylnemorone, the percentage of cells in the G1 phase decreased
with a corresponding increase in the S phase cells. After 24 hours, the percent of S-phase
cells decreased and the percentage of cells in the G2/M phase increased. The increase in
G2/M phase cells continued until 72 hours of incubation with deacetylnemorone, at
which point the percentage of cells in the G2/M phase outnumbered the percentage of
cells in the S-phase. This trend was not seen on cells treated with the vehicle control.
These results suggest that deacetylnemorone may slow progression of the cell cycle
through the S and G2/M phases. While the mechanism is unclear, this could be the result
of DNA damage, inhibition of DNA synthesis, or inhibition of cell cycle regulating cyclins149
With the cancer cell growth inhibition properties of deacetylnemorone
established, the effect of the compound on other cancer-related pathways was then
examined. Deacetylnemorone was observed to reduce SK-MEL-5 invasion at a
concentration as low as 0.3 µM after 24 hours of treatment. The decrease in invasion was
concentration dependent, and the decrease became significant (p ≤ 0.05) at 30 µM of the
compound. Both the migration of the cell front and the invasion of single cells into a cell
free gap between cell fronts were inhibited as deacetylnemorone was added to the cell
culture media. The inhibition of cell front migration could be interpreted as an extension
of the cell growth inhibition observed previously, as the cell front will migrate when the
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cells divide. However, the decrease in single cells invading the cell free gap suggests that
the cells were being inhibited from undergoing epithelial-mesenchymal transition (EMT).
This process allows cancer cells to detach from their extracellular matrix, move freely
within the body, and reattach in a new location, establishing metastatic growth150. Cancer
cells undergoing this process may also be linked to innate chemotherapy resistance and
an increased percentage of cancer stem cells147. The decrease of single cells in the cell
free gap suggests a decrease in the number of cells that had migrated from one of the cell
fronts. This inhibition is unique from cell growth inhibition and may lead to an ability of
deacetylnemorone to inhibit the metastasis and chemotherapy resistance of melanoma.
The final cancer-related pathway that was assayed for a response to deacetylnemorone
was angiogenesis. At sub-cytotoxic concentrations of deacetylnemorone (0.3 and 3 µM),
significantly less tube formation was observed between HUVEC endothelial cells. Tube
formation is a crucial step in angiogenesis, which is required for both extended tumor
growth and metastatic formation. By inhibiting the formation of tubes between
endothelial cells, deacetylnemorone may cut off the blood supply to new and growing
tumors and further inhibit metastasis.
3.6 CONCLUSIONS
Deacetylnemorone is a natural product of the abietane diterpenoid family. While
limited growth inhibition studies have been performed to investigate the potential of this
compound, it has remained an understudied lead compound for anti-cancer therapy. In
this study, deacetylnemorone was shown to inhibit cell growth of a wide variety of cancer
cell lines, induce non-apoptotic cell death in SK-MEL-5 melanoma, sensitize HCT 116/200
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resistant colorectal carcinoma to chemotherapeutic treatment, inhibit the EMT and
invasion of melanoma cells, and inhibit angiogenesis. These properties may give
deacetylnemorone the ability to provide a robust, multi-targeted treatment for a range
of cancers, which not only increases the efficacy of current cancer treatment
combinations and reduces the risk of treatment-acquired resistance, but also re-sensitizes
already resistant tumors to further chemotherapy use. Further examination is warranted
to elucidate the mechanism by which each of deacetylnemorone’s anti-cancer effects are
produced in addition to translating these in vitro results in vivo. Additionally, the ability
of deacetylnemorone to target cancer stem cells specifically should be investigated as a
potential mechanism for the ability of the compound to inhibit cell growth in
chemotherapy resistant cell lines and inhibit EMT. In summary, deacetylnemorone is a
multi-targeted natural product which has the potential to enhance currently utilized
cancer treatments when used in combination with chemotherapeutic, anti-angiogenic,
and other targeted therapies.
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3.7 FIGURES

Figure 3.1: The structure of the abietane diterpenoid, deacetylnemorone.

58

Figure 3.2: Waterfall plot of the growth percent of 59 cell lines in response to 10 µM of
deacetylnemorone, determined by the NCI-60 one dose screening test. The tissue type of
each cell line is denoted by color (Purple – Ovarian Cancer, Pale pink – Breast Cancer,
Aqua – Prostate Cancer, Grey – CNS cancer, Gold – Renal Cancer, Bright Pink – Melanoma,
Green – Colon Cancer, Blue – Non-small cell lung cancer, Red – Leukemia).
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Figure 3.3: Percent viability of A) MG-63, B) SK-OV-3, C) MDA-MB-231, D) HCT 116, E) HCT
116/200, and F) A2780ADR cells in response to various concentrations of
deacetylnemorone after 48 and 72 hours of exposure, as determined by the MTS
cytotoxicity assay. For all cell lines except A2780ADR, the concentration of doxorubicin
was 2 µM. For the A2780ADR cell line the concentration of doxorubicin was 1 µM. *
denotes a significant difference (p < 0.05) from the control group. ** denotes a significant
difference (p < 0.05) from the previous concentration in addition to the control group.
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Figure 3.4: The A) percent viability and B) cell number of the HCT 116/200 cell line in
response to a 48 hour exposure of various concentrations of deacetylnemorone, alone or
in combination with the chemotherapy agent FdUrd, as calculated using the MTS assay. *
denotes a viability significantly lower than the control. ** denotes a viability significantly
lower than the 4 µM FdUrd treatment. *** denotes a viability significantly lower than
both the 4µM FdUrd treatment and the preceding natural compound concentration. In
all cases, significance is defined by a two tailed t-test with p < 0.05.
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Figure 3.5: Histogram of propidium iodide expression as measured by flow cytometry for
SK-MEL-5 cells treated with either a vehicle control or 15 µM of deacetylnemorone. The
histograms A.) were divided into four sections representing the sub-G1, G0/G1, S, and
G2/M phases of the cell cycle. The histograms were used to calculate the percentage of
analyzed cells treated with B) the vehicle control and C) 15 µM deacetylnemorone.
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Figure 3.6: Invasion of SK-MEL-5 melanoma cells into a cell-free gap created using a 2well cell culture insert when incubated with different concentrations of
deacetylnemorone for 24 hours. A) A representative image of the cells at 0 and 24 hours
after insert removal and the addition of deacetylnemorone. B) The percent invasion of
the cells after 6, 12, or 24 hours. A significant difference, p ≤ 0.05, from the control at the
same time point is denoted by *.
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Figure 3.7: A) The average number of junctions, or tubes, formed between HUVEC
endothelial cells after 8 hours of incubation on growth factor reduced BD Matrigel, where
* represents a significant difference (p < 0.05) from the control group. A representative
bright field image is shown for treatment with B) growth media alone, C) 0.3 µM
deacetylnemorone, and D) 3 µM deacetylnemorone. E) The percent viability of HUVEC
endothelial cells in response to 8 hours of incubation with various concentrations of
deacetylnemorone as determined by an MTS assay. The control group was treated with
culture media alone, and the DMSO group was treated with 0.05% DMSO in culture
media.
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CHAPTER 4
A MULTI-TARGETING NATURAL PRODUCT WITH CHEMOTHERAPEUTIC,
IMMUNE-MODULATING, AND ANTI-ANGIOGENIC PROPERTIES3

4.1 ABSTRACT
Targeted therapies have changed the treatment of cancer, giving new hope to
many patients in recent years, but also coming with serious hurdles. These hurdles have
resulted in cancer remaining the second leading cause of death in the United States with
over a quarter of these deaths coming as a result of lung and bronchus cancers. The
shortcomings of targeted therapies including acquired resistance, limited susceptible
patients, high cost, and high toxicities, has led to the necessity of combining these
therapies with other targeted or chemotherapeutic treatments in order to reduce the
required doses and increase efficacy. Natural products are uniquely capable of synergizing
with targeted and non-targeted anticancer regimens due to their ability to affect multiple
cellular pathways simultaneously. Compounds which provide an additive effect to the
often combined immune therapies and cytotoxic chemotherapies, are exceedingly rare.
Compounds of this nature would however provide a strengthening bridge between the
two treatment modalities, increasing their effectiveness and improving patient
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prognoses. In this study, clusianone, a natural acylphloroglucinol, was investigated for its
anticancer properties. While previous studies have suggested clusianone and its
conformational isomers are anti-cancer agents, very few cancer types have been
demonstrated to exhibit sensitivity to these compounds and little is known about the
mechanism by which clusianone inhibits cancer cell growth. In this study, clusianone was
shown to inhibit the growth of 60 cancer cell types and induce significant cell death in 25
cancer cell lines. The compound was further shown to modulate the immune system by
polarizing macrophages to an M1 anti-cancer state. Mechanistic studies were also
performed to demonstrate the effect of clusianone on non-small cell lung cancer,
specifically. The compound was shown to induce G1 cell cycle arrest followed by
apoptosis, as confirmed by flow cytometry and western blot analysis. Three direct targets
of clusianone, namely tubulin polymerization, JAK3 kinase, and ALK (C1156Y) were
identified. Clusianone was finally demonstrated to inhibit the invasion of non-small cell
lung cancer and angiogenesis, suggesting an ability to prevent growth and metastasis of
non-small cell lung cancer. The multi-targeted anticancer effect of clusianone on cancer
cell growth, cancer cell invasion, immune regulation, and angiogenesis makes it a
promising lead compound for drug discovery, especially as a combinatorial treatment
alongside targeted therapies for lung cancer.
4.2 INTRODUCTION
In recent years, new hope has been given to patients diagnosed with cancer due
to the emergence of targeted therapeutics151. However, due to the limitations of newly
discovered targeted therapies, cancer remains the second leading cause of death in the
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United States according to the Centers for Disease Control and Prevention152, 153. Of the
approximately 610,000 deaths caused by cancer in 2018, over 25% will be due to lung and
bronchus cancers, making them the deadliest cancer type in the United States1. The use
of

targeted

therapies

has

represented

a

paradigm

shift

from

traditional

chemotherapeutics (often derived from multi-targeting natural products) to molecules
and antibodies affecting specific cellular functions. Within the category of targeted
therapies, immune modulating therapies have been the source of many novel treatments.
Monoclonal antibodies118, cytokines

119

, dendritic cell therapies120, chimeric antigen

receptor T cells (CAR-T cells)121, and immune checkpoint blockade therapies122 are among
the immune modulating treatments that have been approved by the Food and Drug
Administration (FDA) for the treatment of cancer.
Each of these emerging technologies has led to an increase in treatment responses
and survival times, however, major drawbacks have been identified for each. For
example, the dendritic cell therapy, sipuleucel-T, which is made by isolating a patient’s
antigen presenting cells, then activating the cells with prostatic acid phosphate and
granulocyte-macrophage colony-stimulating factor, and finally reintroducing the cells
back into the patient has been shown to be effective in treating early metastatic
castration-resistant prostate cancer. However, sipuleucel-T treatment is extremely costly
due to the personalized nature of the treatment and often must be combined with other
treatments, including radiation or chemotherapy, to successfully treat the patient125.
CAR-T cell therapies, including tisagenlecleucel and axicabtagene ciloleucel, similarly
function by isolating T cells from a patient and genetically engineering them to express
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the chimeric antigen receptor to target cancer cells. While tisagenlecleucel holds much
promise for the treatment of leukemia, as well as the distinction of being the first FDA
approved gene therapy treatment in the United States, it also comes with a record setting
$475,000 price tag2. In addition, CAR-T cell therapies have been associated with
neurotoxicities and cytokine release syndrome, leading to high fever, hypotension,
hypoxia, and respiratory distress126. Other immune regulating treatments, including
immune checkpoint blockade therapies such as nivolumab, tend to be more cost effective
but less personalized to each patient. Nivolumab acts by inhibiting the programmed cell
death protein 1 (PD-1) checkpoint which reduces the immune surveillance evasion of
cancer cells. This therapy has been shown to have a higher objective response rate and a
prolonged progression-free survival compared to traditional chemotherapy in melanoma
patients3, yet the treatment is not effective in tumors with low mutational burden or
lower immunogenicity. Additionally, resistance development is common even in settings
with initially favorable responses127. As a result, these treatments are often used in
combination with other therapies. Modulation of the activity of macrophages found
within the tumor microenvironment has also garnered interest as a potential immune
regulating cancer therapy, though the FDA has not currently approved a macrophagetargeted therapy154.
Targeted therapies used to disrupt the unregulated growth signals of mutated
proto-oncogenes or disrupt angiogenesis have similarly changed the landscape of cancer
treatment despite being accompanied by major drawbacks. For many years, the first-inline treatment for metastatic melanoma was the alkylating agent dacarbazine, until the
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advent of the B-rapidly accelerated fibrosarcaoma (BRAF) inhibitor, vemurafenib. This
targeted therapy increased the objective response rate to treatment from 5% to 48% in
BRAFV600E mutant metastatic melanoma and paved the way for numerous BRAF and
mitogen-activated protein kinase/extracellular signaling regulated kinases (MEK)
inhibitors to be used in the treatment of the disease155. However, innate resistance to
immune checkpoint blockade has been observed in 40–50% of metastatic melanoma
patients, and BRAF/MEK inhibitors have only increased the median progression free
survival of susceptible melanoma patients to 9–11 months due to the short lived efficacy
156

. Angiogenisis targeting therapies such as bevacizumab and sorafenib have been used

to treat solid and metastatic tumor growth, but similarly suffer from acquired resistance,
likely as a result of plasticity of the tumor microenvironment6. The disappointing
performance of targeted therapies has led to a renewed interest in multi-targeting
natural products76.
Natural products have a long history of use as cancer therapies, either being used
for or inspiring approximately 60% of cancer treatments used between 1981 and 200672.
These compounds tend to be safe and low cost in addition to targeting a number of
cellular functions simultaneously. By targeting multiple cancer related pathways, natural
compounds may be able to provide a robust, widely applicable treatment less susceptible
to resistance. Natural products targeting the immune response in addition to inducing
cancer cell death are uniquely positioned to synergize well with current treatment
regimens. Compounds of this type may be able to limit the number of immune therapies
and chemotherapies used in cancer treatment cocktails in addition to increasing their
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efficacy. The number of compounds with combined chemotherapeutic and immunemodulatory effects is limited, and many of these compounds are classified as natural
products157. Notable examples include astragaloside IV 136, 137, curcumin133, emodin134, 135,
and total saponins of panax ginseng158, 159. These compounds have been demonstrated to
induce apoptosis in cancer cells while simultaneously altering cytokine expression or
macrophage polarization. However, the low bioavailability and limited efficacy of these
compounds warrants further drug discovery efforts for multi-targeting compounds.
Clusianone and its configurational isomers are natural products that have been
demonstrated to feature antimicrobial, anti-allergenic, schistosomicidal, and antiinflammatory effects160-163. Additionally, these compounds have been shown to induce
cell death in glioblastoma, as well as lung, melanoma, breast, prostate, renal, cervical, and
tongue cancer164-167. Researchers have identified several potential molecular targets of
clusianone, including microtubules, the mitochondrial membrane, cathepsins, and
cyclins164, 166-168. It is likely that multiple molecules are targeted by clusianone due to the
so-called “privileged structures” typically possessed by natural products. Limited in vivo
studies have demonstrated the safety of a common configurational isomer of clusianone,
7-epiclusianone, in vivo in administrations of up to 300 mg/kg of body weight in female
albino mice160. Additionally, the chemical synthesis of clusianone and its configurational
isomers have been explored, allowing for a high availability of the compounds169. As a
result, clusianone is a promising lead compound for multi-targeted cancer treatment.
However, screening of clusianone across a wide range of cancers has not yet been
reported. Additionally, only limited studies of the molecular targets of clusianone have
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been performed, and the direct interaction of clusianone and its purported targets has
yet to be determined. Finally, the effect of clusianone on the anticancer immune response
has not been explored. To address these knowledge gaps, herein the combined anticancer
and immune modulatory effects of clusianone are examined.
4.3 MATERIALS AND METHODS
4.3.1 CLUSIANONE SOURCE AND IDENTIFICATION
The acylphloroglucinol, clusianone, was obtained through collaboration with the
University of Basel. We independently confirmed the identity of the compound by 1D and
2D nuclear magnetic resonance (NMR) in addition to time of flight mass spectrometry.
For NMR analysis, clusianone was dissolved in dimethyl sulfoxide (DMSO) and analyzed
using a Bruker Avance III-HD 400 MHz. 1H-NMR, 13C-NMR, H-H correlation spectroscopy
(COSY), heteronuclear single quantum coherence (HSQC), and heteronuclear multiple
bond correlation (HMBC) spectrums were generated. For mass spectrophotometry
analysis, clusianone was dissolved in methanol and analysed using liquid
chromatography-mass spectrometry (LC-MS) on a Thermo Orbitrap Velos Pro. NMR and
mass spectrometry (MS) data can be found in Figures A.4 and A.5. For all cell culture
experiments, clusianone was diluted in dimethyl sulfoxide (DMSO; Santa Cruz
Biotechnology) at a concentration of 20 mM before being diluted into the cell culture
media specified for each cell line.
4.3.2 CELL LINES AND REAGENTS
The non-small-cell lung cancer cell line, NCIH460, was purchased from the
Development Therapeutics Program, Division of Cancer Treatment and Diagnosis tumor
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repository. THP-1 human monocytic cells were obtained from American Type Culture
Collection (ATCC). All cells were stored in liquid nitrogen until use. THP-1 cells were
maintained in Roswell Park Memorial Institute (RPMI-1640) medium (Corning)
supplemented with 10% Fetal Bovine Essence (FBE; VWR), and 0.05 mM 2mercaptoethanol (Sigma-Aldrich). NCIH460 cells were maintained in RPMI-1640 media
supplemented with 10% FBE and 2 mM L-glutamine (Sigma) in a 5% CO2, 37°C, humidified
incubator. THP-1 cells were differentiated into M0 macrophages by culturing the cells
with 100 ng/ml of 12-myristate 13-acetate (PMA; Sigma) for 24 h. After differentiation,
the cells were washed three times with serum free RPMI-1640 medium (Gibco) to remove
non-differentiated cells.
4.3.3 NCI-60 CELL LINE SCREENING
Cytotoxicity screening was performed using the National Institute of Health’s
(NIH) National Cancer Institute-60 (NCI-60) screening program144. The screening of 60 cell
lines was performed by the NIH using a Sulforhodamine B cell viability assay, as described
by Shoemaker145. After sufficient activity was observed using one dose of clusianone (20
µM), the screening was repeated using a five-point dilution. Three concentrations,
including the growth inhibition of 50% (GI50), total growth inhibition (TGI), and lethal
concentration of 50% (LC50), were determined for each cell line in the screening assay
using the five-dose data results.
4.3.4 IN VITRO INVASION ASSAY
Cell migration of NCIH460 cells was assessed by making a cell-free gap with a
Culture-Insert 2 well 24 (IbiTreat) (Martinsried, Germany), consisting of two wells that
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were separated by a wall. A total of 70 µL of cell suspension containing 6×104 NCIH460
cells was added to each well. Cell migration of THP-1 M0 macrophages was assessed in
the same manner using 75 µL of cell suspension containing 100,000 cells per well. Cells
were given 24 hours to attach and reach confluency. Culture inserts were then removed
and any cell debris was washed with phosphate buffered saline (PBS; Corning). The
samples were supplemented with different concentrations of clusianone in cell culture
media and incubated at 37 °C and 5% CO2 for 24 hours. Images were taken at different
time intervals using a phase contrast Nikon Eclipse Ti-E inverted microscope.
Quantification of the percent invasion was performed by measuring the gap distance
using the following formula,
𝑖𝑛𝑣𝑎𝑠𝑖𝑜𝑛 % =

(𝑊0 − 𝑊𝑛 )
∗ 100%
𝑊0

where 𝑊𝑛 is the average of three gap width measurements at 6, 12, or 24 hours, and 𝑊0
is the initial width of the cell-free gap. The media was removed and 400 µL of Cell Stain
Solution (Cell Biolabs, Inc) was added to each well. The staining solution was incubated
with the cells for 15 minutes at room temperature. The solution was then aspirated and
discarded. Each stained well was washed with deionized water, then the water was
discarded and the cells were allowed to dry at room temperature. Images were taken
using a phase contrast inverted microscope (Invitrogen EVOS FL Auto Cell Imaging).
4.3.5 TUBE FORMATION ASSAY
Growth factor reduced BD MatrigelTM (Corning) was stored at -20°C long term.
Before use, the MatrigelTM was thawed on ice at 4°C overnight. Next, 50 µL of MatrigelTM
was added to each well of a pre-chilled 96-well plate and incubated at 37°C and 5% CO2
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for 30 minutes until the MatrigelTM had formed a gel. A suspension of 20,000 human
umbilical vein cells (HUVEC) in 100 µL of cell culture media dosed with clusianone was
added to each well. The vehicle control consisted of only HUVEC cells and growth media.
At the end of the 8 hour time point, the cells were stained Cell Stain Solution as outlined
in the in vitro invasion assay protocol. The junctions, or tubes, connecting the endothelial
cells were photographed using an Invitrogen EVOS FL Auto at 4x magnification and
counted manually.
4.3.6 CELL CYCLE ANALYSIS
The effect of clusianone on the cell cycle of NCIH460 cells was determined using
flow cytometry. The cells were seeded in 6 well plates at a density of 250,000 cells per
well with 2 mL of media and were incubated overnight to allow the cells to attach. The
media was then removed and replaced with media supplemented with clusianone. At 6,
12, 24, and 48 hours of treatment with clusianone the drugged media was collected and
the cells were trypsinized with 0.25% trypsin (Corning). The detached cells were then
combined with the media for each treatment and centrifuged at 2500 rpm for 5 minutes.
The supernatant was discarded, and the pellet was washed and centrifuged with ice-cold
PBS twice. The resulting pellet was suspended in 1 mL of ice-cold PBS, which was then
added dropwise to 3 mL of ice-cold 70% ethanol in deionized water. The suspension was
kept at 4°C for at least 24 hours to allow the cells to fix. Once all time points had been
collected, the cells were again centrifuged and the resulting pellets were suspended in
FxCycle PI/RNase Staining Solution (Invitrogen) for 15 minutes, then analyzed using a BD
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LSR II flow cytometer. Propidium iodide (PI) expression was used to quantify the
percentage of cells in the sub-G1, G0/G1, S, and G2/M phases.
4.3.7 ANNEXIN V/PI APOPTOSIS ASSAY
The ability of the clusianone to induce apoptosis in NCIH460 cells was determined
using the FITC Annexin V/ Dead Cell Apoptosis Kit (Invitrogen). The cells were seeded in 6
well plates at a density of 200,000 cells with 2 mL of media per well and were incubated
overnight to allow the cells to attach. The media was then removed and replaced with
media supplemented with clusianone or a vehicle control, 0.3% DMSO in RPMI 1640
media supplemented with 10% fetal bovine essence and 2 mM L-glutamine. After 48
hours of incubation, the media was collected, and the cells were trypsinized with 0.25%
trypsin. The detached cells were then combined with the media for each treatment and
centrifuged at 2500 rpm for 5 minutes. The supernatant was discarded, and the pellet
was washed with ice cold PBS, centrifuged, and resuspended in Annexin V buffer
(Invitrogen) at 1,000,000 cells/mL. Next, 100 µL of the cell suspensions were added to
flow cytometry tubes, and 5 µL of Annexin V/FITC antibody and 1 µL of PI working solution
(Invitrogen) were added to each sample. The samples were incubated for 15 minutes at
room temperature and analyzed using a BD LSR II flow cytometer.
4.3.8 WESTERN BLOTTING
The effect of clusianone on apoptosis related proteins in NCIH460 cells was
assessed using western blotting. The cells were seeded in T-25 flasks (VWR) at a density
of 1.5x106 cells in 5 mL of media. The cells were allowed to attach for 24 hours. After the
cells had attached, the media was replaced with media supplemented with either a
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vehicle control or the designated concentration of clusianone. After 12 and 24 hours, one
flask of each treatment group was selected, the media was removed and replaced with
PBS, and the cells were detached by scraping. The cells were then centrifuged at 2500
rpm for 5 minutes and the supernatant was discarded. The cells were then lysed by
suspending the pellet in Radio-immunoprecipitation assay (RIPA) buffer (CST)
supplemented with phenylmethylsulfonyl fluoride (PMSF) (Sigma-Aldrich) at a
concentration of 400 µL/ 107 cells. The suspension was incubated on ice for 5 minutes,
briefly vortexed, and sonicated for 45 seconds. The suspension was then centrifuged at
14,000 g for 10 minutes at 4°C. The supernatant containing the extracted protein was
collected. Protein concentration was determined by the bicinchoninic acid (BCA) assay
following the manufacturer’s protocol.
Protein extract was then diluted in RIPA buffer and 4x Laemmli sample buffer (BioRad), heated at 95°C for 5 minutes, cooled, and briefly centrifuged. Approximately 50 µg
of protein was loaded into each well of 12% Mini-Protean TGX Stain-Free Gels (Bio-Rad).
The gels were electrophoresed in sodium dodecyl sulfate (SDS) running buffer (CST) at 70
V for approximately 90 minutes using a mini-protean tetra cell electrophoresis chamber
(Bio-Rad). The proteins were transferred to a 0.2 µm pore size nitrocellulose membrane
using Tris-Glycine transfer buffer (CST) in a Criterion wet blotter (Bio-Rad) at 70 V for 90
minutes. The membrane was washed with Tris buffered saline (TBS) (CST) and blocked
with 5% milk (CST) in TBS for 1 hour. The membrane was then washed with TBST and
treated with primary antibody diluted 1:1000 in 5% bovine serum albumin (BSA) in TBS
with Tween (TBST) at 4°C overnight. All primary antibodies were purchased from CST and
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were sourced from rabbit. The membrane was again washed with TBST before incubating
the membrane in anti-rabbit horseradish peroxidase (HRP)-linked secondary antibody
(CST) diluted 1:2000 in 5% milk in TBST for 1 hour. The membrane was washed with TBST
a final time, then incubated with SignalFire reagent for 2 minutes and imaged using a
BioRad ChemiDoc MP Imaging system. If a membrane was re-probed for a different
protein, the membrane was stripped using Restore western blot stripping buffer
(Thermo).
4.3.9 TUBULIN POLYMERIZATION ASSAY
Tubulin polymerization was assessed using the Tubulin Polymerization Assay Kit
from Cytoskeleton as per the manufacturer’s instructions. Clusianone was diluted in
DMSO at 20 mM before being diluted to a 10x solution in General Tubulin Buffer.
Paclitaxel was used as the positive control. Absorbance correlating to the extent of
polymerization was recorded every minute for a total of one hour. Each experimental
group was repeated in triplicate.
4.3.10 DISCOVERX KINASE PANEL
Clusianone was submitted to the DiscoverX KINOMEscan scanTK panel to
determine its ability to directly inhibit the function of 135 tyrosine kinases. The assay is
an active site-directed competition assay, which does not require the use of ATP to assess
kinase function. One concentration of clusianone (20 µM) was tested in the panel, and
the results were reported as the percent of remaining function for each kinase upon
treatment with clusianone.
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4.3.11 MACROPHAGE CYTOTOXICITY ASSAY
Macrophage viability in response to clusianone treatment was assessed using
CellTitter 96 Aqueous Non-Radioactive Cell Proliferation assay (Promega). THP-1 cells
were seeded into 96-well tissue culture plates at a density of 100,000 cells/well with a
total volume of 100 µL of complete growth media (RPMI-1640 media supplemented with
10% Fetal Bovine Essence, and 0.05 mM 2-mercaptoethanol) with the addition of 100
ng/ml of PMA in each well. Cells were incubated for 24 hours at 37°C and 5% CO2 to allow
for cell differentiation to M0 macrophages. After differentiation, the cells were washed
three times with serum free RPMI-1640 medium to remove non-differentiated cells. After
cell differentiation, the cells were exposed to various concentrations of clusianone for 75
hours. Then, the cells were washed with PBS, and culture media supplemented 20% 3(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2Htetrazolium (MTS) solution (Promega) was added to the cells. The cells were incubated
for 2 hours, and the absorbance of each well at 490 nm was measured using a Spectramax
190 microplate reader.
4.3.12 ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA)
THP-1 cells were differentiated in a 24-well plate at a density of 300,000 cells/well
with a total volume of 1.5 ml of culture media per well. After the 72 hours of treatment
with clusianone the culture media was collected from all the experimental groups. The
media was centrifuged at 2500 rpm for 5 min and stored at -20 °C. The concentrations of
tumor necrosis factor alpha (TNFα) and interleukin-6 (IL-6) in the THP-1 media were
evaluated using human IL-6 and TNFα

tetramethylbenzidine (TMB) enzyme-linked
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immunosorbent assay (ELISA) development kits (Peprotech) according to the
manufacturer’s protocol. Colorimetric changes were measured using a SpectraMax 190
microplate spectrophotometer at 450 nm with wavelength correction set at 620 nm.
Standard curves for each cytokine were run in parallel to convert the absorbance to
concentration in each group.
4.3.13 RNA EXTRACTION AND QUANTITATIVE REAL-TIME POLYMERASE CHAIN REACTION
(RT-PCR)
Total RNA was isolated using the Gene Jet RNA Purification kit (Thermo Scientific)
according to the manufacturer’s instructions. The quantification of the ribonucleic acid
(RNA) was measured using a Thermo Scientific Nanodrop 2000c spectrometer and
considered pure if the ratio of absorbance at 260 nm/280 nm was ≥ 2. RNA isolates were
stored at -20 ̊C until they were used for reverse transcription polymerase chain reaction
(rt-PCR). The RNA was prepared as a template for complementary deoxyribonucleic acid
(cDNA) synthesis using the iScript cDNA Synthesis kit (Bio-Rad). Quantitative rt-PCR
analysis was performed with the synthesized cDNA and SYBER® Green PCR Supermix (BioRad). Gene expression was normalized to the housekeeping gene glyceraldehyde 3phosphate dehydrogenase (GAPDH) and the control group, non-treated THP-1 M0
macrophages (2-ΔΔC). Gene expression values were calculated by using the mean cycle
threshold (CT) values of the samples. All primers (Table S1) were synthetized by
Integrated DNA Technologies (Coralville).
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4.4 RESULTS
4.4.1 CLUSIANONE INHIBITS CELL GROWTH AND INDUCES CELL DEATH IN A WIDE
SPECTRUM OF CANCERS.
To determine the cytotoxic potential of clusianone (Figure 4.1), the compound
was screened against the 60 cancer cell lines of the National Cancer Institute’s NCI-60
cancer panel. This panel utilizes a Sulforhodamine B assay to quantify the total cellular
protein present after 48 hours of treatment with a compound of interest. The panel
screens 60 unique cancer cell lines across 9 different tissue types including leukemia, nonsmall cell lung cancer, melanoma, breast cancer, central nervous system (CNS) cancer,
renal cancer, ovarian cancer, and prostate cancer. For each of the cell lines, the
concentration of compound required to reduce the growth of cells to 50% that of the
vehicle control (GI50), the concentration required to inhibit the growth of any amount of
cells (TGI), and the concentration required to induce cell death of 50% of the seeded cells
(LD50) was determined (Figure 4.2).
Clusianone inhibited the growth of all 60 cell lines in the NCI-60 cancer panel
(Figure 4.2A) with an average GI50 of 2.7 µM. Clusianone did not, however, exhibit a high
level of selectivity in inhibiting the growth of the cancer cell lines as the determined GI50
concentrations only ranged from 1.63 µM to 3.89 µM. The selectivity of clusianone was
higher in completely inhibiting cell growth. The majority of TGI concentrations for cell
lines within the panel were less than 10 µM, however, two leukemia cell lines continued
to grow after 48 hours of incubation with 101 µM of clusianone, the highest concentration
tested (Figure 4.2B). In addition to inhibiting the growth of many cancer cell lines,
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clusianone exhibited an LD50 of less than 101 µM for 25 of the cell lines tested (Figure
4.2C). Interestingly, the cytotoxicity of clusianone varied widely within each tissue type,
with the exception of leukemia, for which no LD50 under 101 µM was observed.
The full growth response data for each of the cell lines can be found in Table S2 As
lung and bronchus cancers are projected to be responsible for over one quarter of all
cancer-related deaths in the United States in 2018, the effect of clusianone on small cell
lung cancer was investigated further. The non-small cell lung cancer cell line, NCIH460,
was the most sensitive lung cancer cell line to clusianone. The GI50, TGI, and LD50
concentrations of the NCIH460 cell line were 2.6 µM, 6.2 µM, and 35µM, respectively
(Figure 4.3).
4.4.2 CLUSIANONE INDUCES G1 ARREST FOLLOWED BY APOPTOSIS IN NCIH460 SMALL
CELL LUNG CANCER CELLS
In order to gain insight into the mechanism of action of clusianone on NCIH460
small cell lung cancer cells, the cell cycle of the NCIH460 cells over 48 hours under
exposure to clusianone was analyzed by quantifying the amount of PI bound to DNA
within the cells using flow cytometry (Figure 4.4). When the NCIH460 cells were treated
with 35 µM of the compound the number of cells in the G1 phase of the cell cycle
increased at 12 and 24 hours of incubation when compared to the vehicle control, 0.2%
DMSO in RPMI 1640 media supplemented with 10% fetal bovine essence. Additionally, a
depletion of cells in the S and G2/M phases of the cell cycle occurred after 24 hours when
compared to the control and persisted after 48 hours. The percent of cells in the S phase
decreased at a rate faster than the percent of cells in the G2/M phase decreased when
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exposed to clusianone, suggesting that cells were progressing from the S phase to G2/M
phase, but they were unable to progress from the G1 phase to S phase when exposed to
clusianone. At the 48-hour time point, the percentage of cells in the G1 phase decreased
when compared to the percent of cells in the G1 phase at 24 hours when exposed to
clusianone. As the percent of cells in the S and G2/M phases continued to decrease over
this same time period, this decrease in G1 phase cells can be explained by the increase in
sub G1 cells seen from 24 hours to 48 hours of incubation with clusianone. These sub G1
cells are hypothesized to be dead cells with cleaved DNA.
Annexin V/PI expression for the NCIH460 cells after 48 hours of incubation with
7.6 µM, 15 µM, 35 µM, and 61 µM clusianone was determined to evaluate whether the
cells observed in the sub-G1 phase had undergone apoptosis (Figure 4.5). As the
concentration was increased the number of live cells decreased, confirming the dose
dependent cytotoxicity of clusianone on NCIH460 cells. In each of the clusianone-treated
groups, the number of apoptotic and necrotic cells increased when compared to the
vehicle control, 0.3% DMSO in RPMI 1640 media supplemented with 10% fetal bovine
essence and 2 mM L-glutamine. The number of apoptotic, Annexin V positive cells
increased as the concentration of clusianone was increased. Additionally, at lower
concentrations, a population of PI positive and Annexin V low cells was observed (Figure
4.5B and Figure 4.5C). This suggests that at lower concentrations, a population of NCIH460
cells were in the process of exposing the Annexin V binding protein, phosphatidylserine,
and therefore were in an earlier stage of apoptosis after 48 hours than were cells treated
with a higher dose of clusianone.
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We also determined the caspase activity of the NCIH460 cells to confirm the
occurrence of apoptosis after exposure to clusianone. The quantity of inactive/full length
and active/cleaved forms of caspases 7, 8, 3, and 9 present with the NCIH460 cells was
determined using western blotting (Figure 4.6). After 12 and 24 hours of exposure to
clusianone, the full length form of caspases 7 and 8 decreased as the concentration of
clusianone was increased, but the cleaved forms of these caspases were not detected. No
trend was apparent from the quantity of caspase 3 detected at either time point.
However, the ratio of cleaved caspase 9 to full length caspase 9 increased dramatically
for NCIH460 cells treated with 7.6 µM or 15 µM of clusianone for 12 or 24 hours.
Additionally, a dose- and time-dependent increase in the ratio of cleaved Poly (ADPribose) polymerase (PARP) to full length PARP occurred under incubation with clusianone.
The cleavage of caspase 9 and PARP further confirm that clusianone induces apoptosis in
NCIH460 lung cancer.
4.4.3 CLUSIANONE INHIBITS ANGIOGENESIS AND CELL MIGRATION OF NCIH460 CELLS
After determining clusianone’s ability to induce cell death at high concentrations,
the ability of clusianone to inhibit cell migration of NCIH460 cells at low concentrations
was assessed. A uniform cell gap was formed using a 2 well cell culture insert, and the
cells were allowed to grow for up to 24 hours exposed to either a vehicle control or
clusianone (Figure 4.7). After 24 hours, the cell-free gap had almost completely closed for
cells treated with the vehicle control. In contrast, after 24 hours of incubation with
clusianone the percent invasion of NCIH460 cells into the cell-free gap was significantly
lower compared to the control for each concentration used, including 200 nM, a
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concentration 10-times lower than the GI50 concentration. At each time point considered
(6, 12, and 24 hours), a dose dependent decrease in invasion was observed.
Similarly, the ability of clusianone to inhibit angiogenesis was indirectly assessed.
HUVEC endothelial cells were incubated with or without clusianone on a growth factor
reduced BD MatrigelTM basement matrix. Tube formation between the endothelial cells
was assessed after 8 hours (Figure 4.8A). A dose dependent reduction of tube formation
was observed when the cells were exposed to clusianone at concentrations between 0.2
and 20 µM (Figure 4.8B). The reduction of tube formation became significant (p≤0.05) at
20 µM clusianone. An MTS viability assay of HUVEC endothelial cells in response to
clusianone for 8 hours revealed that the compound was not toxic at this time point (Figure
4.8C). No significant difference in viability was observed in these cells even at the highest
concentration of 20 µM clusianone.
4.4.4 CLUSIANONE DIRECTLY TARGETS TUBULIN POLYMERIZATION, JAK3, AND ALK
(C1156Y)
While the cytotoxic effect of clusianone on a number of cell lines has been
previously reported, the direct effect of clusianone on its purported molecular targets has
yet to be determined164-167. Due to the identification of microtubules as a potential target
of clusianone in other lung cancer cell lines167, the effect of clusianone on tubulin
polymerization was investigated using the cytoskeleton tubulin polymerization assay
(Figure 4.9). While the nucleation time, i.e., the time required for tubulin to begin
polymerizing, was not affected by the presence of clusianone, the rate at which the
tubulin polymerized was significantly increased by 100 and 200 µM of clusianone (Figure
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4.9A). The rate at which the tubulin polymerized is best represented by the Vmax value,
which corresponds to the highest ratio of increase in the absorbance at 340 nm to time
for each treatment group. We observed a dose dependent increase in Vmax, consistent
with the increase in Vmax observed in the presence of the known microtubule stabilizing
agent, paclitaxel170.
To determine the ability of clusianone to target tyrosine receptor kinases, a
common target of cancer therapeutics, the compound was screened using the DiscoverX
scanTK kinase panel. This panel determines the ability of a compound to inhibit the
activity of 135 different tyrosine kinases. A reduction of kinase activity to 30% or below is
considered significant in this one dose screen. At a concentration of 20 µM, clusianone
significantly inhibited two kinases, anaplastic lymphoma kinase C1156Y (ALK C1156Y) and
janus kinase 3 (JAK3). The activity of ALK (C1156Y) and JAK3 were inhibited by 70% and
75% respectively. ALK (C1156Y) is a mutation of the ALK tyrosine kinase, which has been
associated with acquired resistance to the targeted ALK inhibitor, crizotinab, used for the
treatment of small cell lung cancer171. JAK3 is a kinase that plays a role in the immune
response of several types of cells172.
4.4.5 CLUSIANONE INCREASES THE EXPRESSION OF PRO-INFLAMMATORY CYTOKINES IN
THP-1 MACROPHAGES
In order to determine the effect of clusianone on the immune response, the ability
of clusianone to modulate macrophages was investigated. A shift in M0, naïve
macrophages, to M1 polarized, pro-inflammatory and anticancer macrophages, is
denoted by an increase in inflammatory cytokines, including TNFα and IL-6 among others.
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We assessed the expression of these cytokines by THP-1 macrophages after 72 hours of
incubation with clusianone (Figure 4.10). Both the gene expression of the cytokines and
the concentration of the cytokine excreted into the cell culture media were determined
by quantitative rtPCR (q-rtPCR) and ELISA, respectively. In order to ensure the
concentrations of clusianone tested were safe for the macrophages, the viability and
invasion capability of the macrophages under exposure to clusianone was tested and no
significant changes were observed (Figure A.6). The gene expression of both TNFα and IL6 increased as the concentration of clusianone was increased. At 20 µM of clusianone,
the gene expression of both cytokines had increased 60–70 fold over the expression of
the control, untreated macrophages. While a dose dependent increase in the presence of
each cytokine in the media of the cells also occurred, this increase was not significant
when compared to the control. These results indicate that the M0 macrophages may
polarize to anticancer M1 macrophages in the presence of clusianone.
4.5 DISCUSSION
Natural products have been instrumental in the treatment of cancer and are
currently garnering renewed interest as lead compounds for cancer therapies and
complementary treatments due to the shortcomings of targeted therapeutics.
Compounds which simultaneously affect immune regulation of cancer and induce cancer
cell death may provide a uniquely well suited complementary treatment to current
targeted therapy and chemotherapy regimens. Clusianone and its configurational
isomers, particularly 7-epiclusianone, are natural products that have been shown to
exhibit a wide array of biological effects. The anticancer effects of clusianone have been
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previously investigated in a limited number of cancer cell lines164-167, but the mechanism
of action and the molecular targets of the compound have not been fully investigated,
nor has its ability to modulate the immune response to cancer.
In this study, clusianone was demonstrated to inhibit the growth of cancer cells
across 9 tissue types and 60 individual cancer cell lines. A growth inhibitory effect was
observed for each cell line, but an LD50 less than the highest concentration tested was
only observed in 25 of the 60 cell lines tested. These 25 cell lines were composed of cell
lines from each tissue type tested excluding leukemia. In combination, these effects
suggest that clusianone could be used to slow the progression of many variations of
cancer, but it will not be cytotoxic to all types of cells. As clusianone is likely to be safe in
vivo at relatively high concentrations160 and the compound is selective in inducing cell
death, clusianone has the potential to be safely used for the treatment of a diverse group
of cancers. In particular, renal cancer, melanoma, central nervous system tumors, colon
cancer, and non-small cell lung cancer appear to be sensitive to the cytotoxic effects of
clusianone. It is unclear what factors determine the sensitivity of each cancer cell line to
clusianone, and further study will be required to determine how to best predict sensitivity
to clusianone within a particular cancer tissue. Clusianone’s anticancer effects have the
biggest potential for clinical impact, however, on non-small cell lung cancer due to the
high rate of lung cancer related death in the United States, the ability of the compound
to induce cell death in non-small cell lung cancer cell lines, and the ability of clusianone
to inhibit an ALK tyrosine kinase mutation responsible for acquired resistance to
treatment.
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In order to further investigate the anticancer effect of clusianone on non-small cell
lung cancer, additional experiments were performed on a lung cancer cell line which had
exhibited sensitivity to the compound. The non-small cell lung cancer cell line that
exhibited the greatest sensitivity to clusianone was NCIH460. Clusianone induced dose
dependent cell death in this cell line with a GI50, TGI, and LD50 of 2.6 µM, 6.2 µM, and
35µM, respectively. We determined that cell death in the NCIH460 cell line occurred after
48 hours of treatment with 35 µM of clusianone. Cell cycle analysis revealed that the cell
death was preceded by G1 phase arrest, and a subsequent reduction of S phase and G2/M
phase cells. A similar G1 phase arrest has been observed after treatment of A549 lung
cancer cells with 7-epiclusianone, suggesting that the configurational isomers have similar
mechanisms of action for inducing cytotoxicity in lung cancer167. Furthermore, the cell
death induced by clusianone in NCIH460 cells was shown to proceed through an apoptotic
mechanism. As the concentration of clusianone was increased, more apoptotic cells were
observed using flow cytometry. Apoptosis was confirmed by the cleavage of caspase 9
and PARP, which participate in the caspase cascade leading to cell death after
mitochondrial depolarization has occurred173, 174. We also observed a decrease in full
length caspase 7 and caspase 8 expression upon treatment of NCIH460 cells with
clusianone. The decrease in full length caspase 7 was further evidence that the caspase
cascade leading to apoptotic cell death had been activated. The decrease in full length
caspase 8 in addition to the activation of caspase 9 suggested that both the extrinsic,
receptor mediated apoptosis pathway and the intrinsic apoptosis pathway were
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activated174. This finding is not conclusive, however, as no cleaved caspase 8 was detected
at either 12 or 24 hours of incubation with clusianone.
In addition to inducing dose dependent apoptosis in non-small cell lung cancer,
clusianone also inhibited the invasion of NCIH460, non-small cell lung cancer. Significant
invasion inhibition was observed at a concentration as low as 200 nM. Further, clusianone
was shown to significantly reduce the tube formation between HUVEC endothelial cells
at a concentration of 20 µM. Tube formation is a critical step in the process of
angiogenesis which is utilized by the wound healing process as well as by cancers to feed
tumor growth124, 175. By inhibiting angiogenesis and tumor cell invasion, clusianone may
act to inhibit continued tumor growth and metastasis of non-small cell lung cancer into
healthy tissue. These effects were seen in concentrations less than the concentrations
required to induce cell death, suggesting clusianone directly inhibits molecular targets
associated with angiogenesis and invasion which were outside the scope of this study.
Mechanistic studies were however performed to elucidate the mechanism by
which clusianone induces cell death in non-small cell lung cancer. For the first time, the
direct effect of clusianone on cancer proliferation targets including microtubules and ALK
(C1156Y) was determined. While 7-epiclusianone has been previously suggested to
impact microtubule structure

167

, the mechanism of this effect was unclear. This study

demonstrated that clusianone acts by stabilizing and increasing the rate of polymerization
of tubulin directly. This mechanism of action is one shared by chemotherapy agents, such
as paclitaxel, though the concentration of clusianone required to impact the
polymerization of tubulin was high compared to the concentration necessary to induce
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growth inhibition or cell death on NCIH460 cells. As a result, it is likely that additional
molecular targets are influenced by clusianone in order to impart its cytotoxic effects. We
further determined that clusianone directly inhibits the function of two tyrosine kinases,
ALK (C1156Y) and JAK3. While these molecular targets are not largely present within
NCIH460 lung cancer, and thus are not likely to be involved with a mechanism of cell
death, they do suggest clusianone may target non-small cell lung cancer cells with
acquired resistance to kinase inhibitors.
Due to the increasing role of immune targeted therapies in lung cancer, the ability
of clusianone to modulate the immune system within the tumor microenvironment was
also investigated176. Macrophages are immune cells that play a role in T-cell activation in
addition to engulfing pathogens and dead cells. Within the tumor microenvironment,
tumor associated macrophages (TAMs) can be formed, which resemble macrophages
polarized to an M2, anti-inflammatory state and aid in tumor growth and evasion from
the immune system177. While some studies have suggested eliminating TAMs as a
therapeutic strategy, others have hypothesized that polarizing macrophages to the M1
state within the tumor microenvironment will not only eliminate the tumor-supportive
functions of TAMs but will also activate the immune system against the tumor178. In this
study, clusianone was shown to increase the gene expression of TNFα and IL-6 within THP1 derived macrophages, potentially polarizing the cells to an anticancer, proinflammatory M1 state. This regulation of macrophages suggests that clusianone might
be a useful complementary treatment when combined with current first-in-line immune
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therapies. This is especially true in the case of CAR-T cell therapy, in which macrophage
dysfunction is the source of some of the most serious side effects126.
Future studies will be required to determine the effectiveness of clusianone as a
cancer therapy. More mechanistic studies should be performed to elucidate the primary
targets for clusianone’s cytotoxic and immune regulatory properties. Of particular
interest to future studies should be the effect of clusianone on non-small cell lung cancer
due the high mortality rates of this malignancy and the compound’s ability to induce
apoptosis and inhibit invasion of non-small cell lung cancer cell lines. With this
information, the groundwork will be laid to perform in vivo determinations of the efficacy
of clusianone in inducing cancer cell death and regulating the immune response. Special
notice should be paid to the effect of clusianone on the polarization of macrophages
within the tumor microenvironment in these in vivo experiments. Additionally, the
synergistic effect of clusianone when combined with currently approved cancer immune
therapies should be investigated.
Clusianone is a promising lead compound for anticancer therapies due to its
combined apoptotic, anti-angiogenesis, anti-invasion, and immune-regulating properties.
The natural product was shown to have three direct molecular targets in this study, with
more targets likely undiscovered. The multi-targeting nature of clusianone stands to
provide a complementary treatment to emerging targeted oncology therapeutics, which
suffer from limited efficacy when used alone as well as toxicities and acquired resistance.
Additionally, clusianone may combine growth inhibitory and cytotoxic effects on cancer
cells with a modulation of the tumor microenvironment to oppose the formation and
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spread of cancer when used alone. In summary, clusianone may provide a robust and
multipronged treatment for cancer, especially non-small cell lung cancer.
4.6 FIGURES

Figure 4.1: The structure of the polyprenylated acylphloroglucinol natural product,
clusianone.
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A)
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B)
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C)

Figure 4.2: Waterfall plot of the A) GI50, B) TGI, and C) LC50 of clusianone for 60 cell lines
as determined by the NCI-60 five dose screening assay. The tissue type of each cell line is
denoted by color (Purple – Ovarian Cancer, Pale pink – Breast Cancer, Aqua – Prostate
Cancer, Grey – CNS cancer, Gold – Renal Cancer, Bright Pink – Melanoma, Green – Colon
Cancer, Blue – Non-small cell lung cancer, Red – Leukemia). The GI50, TGI, and LC50 was
set to 100 µM if the true concentration was higher than what was tested in the five dose
screen.
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Figure 4.3: Percent growth of NCIH460 non-small cell lung cancer cells after 48 hours of
treatment with clusianone in the NCI-60 panel. The NCI-60 panel is a sulforhodamine B
based screening method of 60 immortalized cancer cell lines. The GI50, TGI, and LD50
concentrations of clusianone for the NCIH460 cells were determined to be 2.6 µM, 6.2
µM, and 35µM, respectively.
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Figure 4.4: Cell cycle flow cytometry experiment showing the A) histogram of propidium
iodide expression of NCIH460 cells after four different time points of treatment with
either a vehicle control or clusianone. The histograms were divided into 4 regions
representing the sub-G1, G1/G0, S, and G2/M phases of the cell cycle. The percentage of
cells in the sub-G1, G1/G0, S, and G2/M regions is shown for both B) the cells treated with
the vehicle control and C) the cells treated with 35 µM of clusianone.
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Figure 4.5: Annexin V/propidium iodide expression of NCIH460 cells exposed to A) a
vehicle control, B) 7.6 µM clusianone, C) 15 µM clusianone, D) 35 µM clusianone, or E) 61
µM clusianone for 48 hours. The expression scatterplots were divided into four quadrants
representing double negative cells, annexin V positive cells, propidium iodide positive
cells, and double positive cells. Double negative cells were considered live cells, annexin
V positive cells were considered early apoptotic cells, propidium iodide cells were
considered necrotic, and double positive cells were considered late apoptotic cells. The
divided histograms were used to express the percentage of cells that were live, early
apoptotic, late apoptotic, or necrotic within each treatment group F).
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Figure 4.6: Expression of apoptosis-related proteins in NCIH460 cells after treatment with
clusianone as determined by electrophoresis followed by western blot analysis. Cells were
treated with clusianone for 12 or 24 hours before loading 50 µg of isolated protein into
each well.
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Figure 4.7: Invasion of NCIH460 cells into a cell free gap created using a 2 well cell culture
insert consisting of two wells that were separated by a wall. After the cells reached full
confluency, the culture insert was removed and the cells were treated with either a
vehicle control or clusianone for 24 hours. A) Representative images of each treatment
group after 24 hours in addition to B) graphs depicting the % invasion of each treatment
group after 6, 12, and 24 hours. All data are statistically presented as the mean ± standard
error. Multiple t-tests were performed using Graph-Pad Prism 7.03 (La Jolla, CA, USA) to
determine the significance between each experimental group. P values of less than 0.05
were considered to be significant. (* denotes significant difference compared to the
control group in the same time point.)
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Figure 4.8: Tube formation between HUVEC endothelial cells after 8 hours of incubation
on growth factor reduced BD MatrigelTM with or without clusianone. A representative
image of the cells treated with the vehicle control, 0.2 µM, 2 µM, and 20 µM clusianone
is shown in part A). The average number of junctions counted per field is graphed in part
B). The viability of HUVEC cells after 8 hours of incubation with clusianone as determined
by MTS assay is shown in part C).
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Figure 4.9: The extent of tubulin polymerization when exposed to clusianone as
determined by absorbance at 340 nm for 1 hour. A) The average absorbance of three
repetitions of the tubulin polymerization assay treated with clusianone, paclitaxel, or a
vehicle control, and B) the average calculated Vmax for each treatment group (*
represents P ≤ 0.05 compared to the control, ** represents 0.05 ≤ P ≤ 0.01 compared to
the control, and *** represents 0.01 ≤ P ≤ 0.001).
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Figure 4.10: Inhibition of 135 tyrosine kinases treated with 20 µM of clusianone
determine using the DiscoverX scanTK kinase panel. The panel uses an active site-directed
competition assay, which does not require the use of ATP to assess kinase function. Data
is presented as a percentage of function after treatment as compared to a vehicle control.
A kinase with a remaining function of 30% or less is considered to be significantly
inhibited. The significantly inhibited kinases, JAK3 and ALK(C1156Y), are highlighted.
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Figure 4.11. Gene and cytokine expression of macrophages treated with clusianone. RNA
expression of THP-1 M0 Macrophage was determined after 72 hours of treatment with
clusianone for A) TNFα and B) IL-6 by quantitative real-time PCR. Gene expression was
normalized to the housekeeping gene GAPDH and the control group, non-treated THP-1
M0 macrophages (2-ΔΔC). Cytokine concentration in culture media was determined for
C) TNFα and D) IL-6 by ELISA assay. P values of less than 0.05 were considered to be
significant. (* denotes significant difference compared to the control group.)

104

CHAPTER 5
SUMMARY
Targeted cancer therapies are revolutionizing cancer treatment, but their full
potential has not been realized due to the occurrence of treatment induced resistance,
the limited number of patients they can treat, and the high cost often associated with
them. Natural products may offer a safe, low cost solution to these problems in a number
of ways. Biologically active natural products tend to influence multiple cellular pathways
simultaneously, making them a source of compounds which can provide a multipronged
attack on cancer cells. When combined with the treatment cocktails containing multiple
targeted therapeutics and chemotherapeutics, natural products may be able to synergize
with multiple components of the treatments in addition to interfering with other cancer
related pathways, such as those responsible for resistance and metastasis.
One way in which natural products may increase the efficacy of targeted cancer
therapies and chemotherapeutics is by inhibiting the growth and function of a small
population of cells called cancer stem cells. These cells have been suggested to be
responsible for acquired drug resistance, metastasis, and tumor recurrence after
remission. A collection of natural products including polyphenols, alkaloids, flavonoids,
and others, have been shown to reduce cancer stem cell populations within tumors,
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reduce invasion and metastasis, and reduce the tumor initiating potential of isolated
cancer cells. Many of these compounds have additionally been shown to target multiple
cancer related cellular pathways from inducing cell cycle arrest and apoptosis to
modulating inflammation. Using the lessons learned from the success of targeted
therapeutics, natural products can be screened for their ability to influence combinations
of cancer related pathways which will provide robust and effective treatment, especially
when combined with currently used clinical treatments.
In this study, two natural products were screened for their multi-targeted effect
on

cancer

pathways.

The

first

compound

was

the

abietane

diterpenoid,

deacetylnemorone. This compound was found to reduce growth inhibition in a wide array
of cancer types in addition to selectively inducing cell deal in SK-OV-3 melanoma cells at
10 µM. The growth inhibitory properties of the compound were shown to be due, in at
least part, to the ability of deacetylnemorone to delay progression of the cell cycle
through the S and G2/M phases. Deacetylnemorone was also shown to increase the
sensitivity of HCT 116/200 colorectal cancer cells to FdUrd, a chemotherapeutic agent
which it had developed a resistance to. The compound was further shown to inhibit two
pathways which lead to tumor growth and metastasis, namely invasion and angiogenesis,
at concentrations as low as 0.3 µM. EMT inhibition was suggested from the invasion
results by a reduced number of single cells found invading the cell free space.
Deacetylnemorone’s ability to reduce treatment induced resistance and inhibit EMT may
suggest that the compound is capable of targeting cancer stem cells.
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The second

compound investigated

was clusianone. Clusianone

was

demonstrated to induce dose dependent growth inhibition and cell death in cancers
across 8 solid tumor cell lines. The compound was investigated further in the context of
lung cancer due to the sensitivity of lung cancer cell lines to the compound in addition to
the exceedingly poor prognoses of lung cancer patients to this day. Specifically,
clusianone was shown to induce G1/G0 arrest followed by apoptotic cell death in NCIH460 non-small cell lung cancer when used at 35 µM concentrations. Activation of the
apoptotic cell death pathways was demonstrated using both Annexin V/propidium iodide
expression flow cytometry and western blotting of caspases and PARP. At lower
concentrations, from 0.2 to 20 µM, the multi-targeting compound was also shown to
inhibit angiogenesis and invasion of NCI-H460 cells. For the first time, specific molecular
targets of clusianone were also identified. The compound stabilized tubulin
polymerization, similar to the chemotherapeutic paclitaxel, between 20 and 200 µM,
potentially contributing to its growth inhibitory properties. Clusianone also significantly
inhibited the function of the kinases ALK (C1156Y) and JAK3, suggesting the compound
may target treatment resistant small-cell lung cancers as well as modulate the immune
system. Indeed, immune modulating properties were demonstrated through the
polarization of macrophages from an M2 to an M1 anticancer state, evidenced by an
increased expression of TNF-𝛼 and IL-6, in response to exposure to the compound from
0.2 to 20 µM.
The results from this study have shown deacetylnemorone and clusianone to be
compounds capable of influencing multiple cancer related pathways simultaneously,
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including angiogenesis, immune regulation, invasion, cell growth, and apoptosis. Future
studies will be necessary to fully determine the mechanism of action for each of these
anticancer effects, in addition to screening of other cancer related pathways. More
importantly, translation of these results to animal models of cancer will need to be
performed. These in vivo experiments should include investigations of clusianone and
deacetylnemorone used in combination with currently used targeted therapies and
chemotherapeutics, to confirm their synergistic effects. By combining these compounds
with currently used treatments, clusianone and deacetylnemorone may lower the hurdles
of resistance to current therapies in addition to expanding the population of treatable
patients.
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APPENDIX A
SUPPLEMENTARY TABLES AND FIGURES
Table A.1: Primers used for quantitative real-time polymerase chain reaction.
Gene

5’-3’ primer sequences: (F: forward R: reverse)
F: CTG CTG CAC TTT GGA GTG AT
TNFα
R: AGA TGA TCT GAC TGC CTG GG
F: AGC CAC TCA CCT CTT CAG AAC
IL-6
R: GCC TCT TTG CTG CTT TCA CAC
F: GTG GAC CTG ACC TGC CGT CT

GAPDH
F: GGA GGA GTG GGT GTC GCT GT

120

Table A.2: Percent growth of the 60 cell lines examined in the NCI-60 five dose screening
method. The cancer cell lines are organized by tissue type.

Leukemia (% Growth)
CCRF-CEM
HL-60(TB)
K-562
MOLT-4
RPMI-8226
SR
Concentration
(logM)

103
94
98
95
96
94
-8.0

102
94
91
96
101
99
-7.0

103
95
96
89
90
100
-6.0

-43
10
-4
-33
5
-5.0

-7
-38
15
-1
-34
1
-4.0

Non-Small Cell Lung Cancer (% Growth)
A549/ATCC
96
103
EKVX
87
90
HOP-62
92
95
HOP-92
98
102
NCI-H226
98
104
NCI-H23
96
95
NCI-H322M
96
94
NCI-H460
107
110
NCI-H522
93
86
Concentration
-8.0
-7.0
(logM)

101
85
96
89
96
92
94
103
81
-6.0

6
-7
-10
-29
-12
-5
-10
-28
-12
-5.0

-70
-34
-44
-57
-44
-36
-57
-69
-21
-4.0

Colon Cancer (% Growth)
COLO 205
97
HCC-2998
94
HCT-116
92
HCT-15
94
HT29
98
KM12
100
SW-620
106
Concentration
-8.0
(logM)

94
97
87
90
97
99
104
-6.0

-22
-26
-44
1
-7
4
12
-5.0

-42
-73
-71
-64
-51
-40
-41
-4.0

98
103
94
97
97
101
106
-7.0
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CNS Cancer (% Growth)
SF-268
97
SF-295
85
SF-539
88
SNB-19
98
SNB-75
72
U251
106
Concentration
-8.0
(logM)

95
91
93
104
79
104
-7.0

94
89
99
100
75
102
-6.0

-29
-39
-38
3
3
2
-5.0

-75
-51
-80
-20
-48
-54
-4.0

Melanoma (% Growth)
LOX IMVI
MALME-3M
M14
MDA-MB-435
SK-MEL-2
SK-MEL-28
SK-MEL-5
UACC-257
UACC-62
Concentration
(logM)

95
89
90
92
93
90
94
100
96
-8.0

96
95
95
96
92
95
96
108
96
-7.0

96
83
90
95
82
92
85
102
85
-6.0

-22
-47
-23
-5
-23
-21
-86
-14
-57
-5.0

-55
-79
-67
-70
-38
-80
-92
-32
-73
-4.0

Ovarian Cancer (% Growth)
IGROV1
102
OVCAR-3
103
OVCAR-4
89
OVCAR-5
88
OVCAR-8
107
NCI/ADR-RES
100
SK-OV-3
95
Concentration
-8.0
(logM)

98
100
99
91
106
99
100
-7.0

97
97
80
87
106
99
99
-6.0

6
-22
-9
10
1
2
-11
-5.0

-33
-70
5
-37
-8
-31
-8
-4.0
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Renal Cancer (% Growth)
786-0
86
A498
100
ACHN
93
CAKI-1
88
RXF 393
101
SN12C
101
TK-10
92
UO-31
88
Concentration
-8.0
(logM)

93
103
99
93
101
99
88
88
-7.0

83
98
93
92
97
96
93
85
-6.0

-33
-60
1
3
-35
2
5
-1
-5.0

-38
-51
-13
-37
-77
-31
-21
-18
-4.0

Prostate Cancer (% Growth)
PC-3
93
DU-145
100
Concentration
-8.0
(logM)

94
100
-7.0

88
97
-6.0

-6
-12
-5.0

-60
-57
-4.0

Breast Cancer (% Growth)
MCF7
86
MDA-MB-231/ATCC
102
HS 578T
101
BT-549
94
T-47D
79
MDA-MB-468
99
Concentration
-8.0
(logM)

88
110
106
100
89
100
-7.0

88
103
105
88
85
96
-6.0

1
-9
-3
-64
-8
-21
-5.0

-11
-42
-18
-80
-14
-44
-4.0
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A)

B)
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C)

D)
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E)

Figure A.1: The A) 1H-NMR, B) 13C-NMR, C) H-H COSY, D.) HSQC, and E) HMBC spectra of
the abietane diterpenoid, deacetylnemorone (in DMSO-d6).
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A)

B)

Figure A.2: The A) negative ion mode time of flight-mass spectrometry and B) negative
mode HR-MS spectra of deacetylnemorone used to determine molecular weight.
127

Figure A.3: Viability of SK-MEL-5 cells after 6, 12, or 24 hours of incubation with
deacetylnemorone. The cells were seeded in 2 well culture inserts within 12 well culture
plates and allowed to reach confluency before being treated with deacetylnemorone.
Viability was determine by manually counting cells excluding trypan blue using a
hemocytometer. (Note no data was collected for the 30µM concentration at 24 hours).
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A)

B)
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C)

D)
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E)

Figure A.4: The A) 1H-NMR spectrum, B) 13C-NMR spectrum, C) H-H COSY spectrum, D)
HSQC spectrum, and E) HMBC spectrum of clusianone in DMSO.
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Figure A.5: Time of flight mass spectrum determination of molecular weight for
clusianone.
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Figure A.6: Cell viability and invasion of macrophages in response to incubation with
clusianone. The effect clusianone on A) the viability of THP-1 macrophages, as determined
by the MTS assay, after 72 hours of exposure to a vehicle control or 0.2, 2, or 20 µM of
clusianone, and B) the percent wound closure of THP-1 macrophages into a cell-free gap
after 24-hour exposure to a vehicle control or 0.2, 2, or 20 µM of clusianone are shown.
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